0000730464--06-30 2025 Q3 false http://www.devryinc.com/20250331#InvestmentInRabbiTrustMember http://www.devryinc.com/20250331#InvestmentInRabbiTrustMember P4Y 0 0000730464 atge:TermLoanMember us-gaap:InterestExpenseMember 2025-01-01 2025-03-31 0000730464 atge:TermLoanMember us-gaap:InterestExpenseMember 2024-07-01 2025-03-31 0000730464 atge:TermLoanMember us-gaap:InterestExpenseMember 2024-01-01 2024-03-31 0000730464 atge:TermLoanMember us-gaap:InterestExpenseMember 2023-07-01 2024-03-31 0000730464 atge:OpenMarketShareRepurchaseProgramsMember 2025-01-01 2025-03-31 0000730464 atge:OpenMarketShareRepurchaseProgramsMember 2024-07-01 2025-03-31 0000730464 atge:OpenMarketShareRepurchaseProgramsMember 2024-01-01 2024-03-31 0000730464 atge:OpenMarketShareRepurchaseProgramsMember 2023-07-01 2024-03-31 0000730464 srt:MaximumMember 2025-03-31 0000730464 us-gaap:TreasuryStockCommonMember 2025-03-31 0000730464 us-gaap:RetainedEarningsMember 2025-03-31 0000730464 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000730464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000730464 us-gaap:TreasuryStockCommonMember 2024-12-31 0000730464 us-gaap:RetainedEarningsMember 2024-12-31 0000730464 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000730464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000730464 us-gaap:TreasuryStockCommonMember 2024-06-30 0000730464 us-gaap:RetainedEarningsMember 2024-06-30 0000730464 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000730464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000730464 us-gaap:TreasuryStockCommonMember 2024-03-31 0000730464 us-gaap:RetainedEarningsMember 2024-03-31 0000730464 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000730464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000730464 us-gaap:TreasuryStockCommonMember 2023-12-31 0000730464 us-gaap:RetainedEarningsMember 2023-12-31 0000730464 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000730464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000730464 us-gaap:TreasuryStockCommonMember 2023-06-30 0000730464 us-gaap:RetainedEarningsMember 2023-06-30 0000730464 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000730464 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000730464 us-gaap:StockOptionMember 2024-06-30 0000730464 us-gaap:StockOptionMember 2023-07-01 2024-03-31 0000730464 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0000730464 us-gaap:PerformanceSharesMember 2024-06-30 0000730464 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2024-03-31 0000730464 us-gaap:PerformanceSharesMember 2023-07-01 2024-03-31 0000730464 srt:DirectorMember us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2025-03-31 0000730464 us-gaap:StockCompensationPlanMember 2022-07-01 2023-06-30 0000730464 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2022-06-30 0000730464 atge:TuitionMember atge:WaldenUniversitySegmentMember 2025-01-01 2025-03-31 0000730464 atge:TuitionMember atge:MedicalAndVeterinaryMember 2025-01-01 2025-03-31 0000730464 atge:TuitionMember atge:ChamberlainUniversitySegmentMember 2025-01-01 2025-03-31 0000730464 atge:OtherServicesMember atge:WaldenUniversitySegmentMember 2025-01-01 2025-03-31 0000730464 atge:OtherServicesMember atge:MedicalAndVeterinaryMember 2025-01-01 2025-03-31 0000730464 atge:OtherServicesMember atge:ChamberlainUniversitySegmentMember 2025-01-01 2025-03-31 0000730464 atge:WaldenUniversitySegmentMember 2025-01-01 2025-03-31 0000730464 atge:TuitionMember 2025-01-01 2025-03-31 0000730464 atge:OtherServicesMember 2025-01-01 2025-03-31 0000730464 atge:DomesticOperationsMember 2025-01-01 2025-03-31 0000730464 atge:ChamberlainUniversitySegmentMember 2025-01-01 2025-03-31 0000730464 atge:BarbadosSt.KittsAndSt.MaartenMember 2025-01-01 2025-03-31 0000730464 atge:TuitionMember atge:WaldenUniversitySegmentMember 2024-07-01 2025-03-31 0000730464 atge:TuitionMember atge:MedicalAndVeterinaryMember 2024-07-01 2025-03-31 0000730464 atge:TuitionMember atge:ChamberlainUniversitySegmentMember 2024-07-01 2025-03-31 0000730464 atge:OtherServicesMember atge:WaldenUniversitySegmentMember 2024-07-01 2025-03-31 0000730464 atge:OtherServicesMember atge:MedicalAndVeterinaryMember 2024-07-01 2025-03-31 0000730464 atge:OtherServicesMember atge:ChamberlainUniversitySegmentMember 2024-07-01 2025-03-31 0000730464 atge:WaldenUniversitySegmentMember 2024-07-01 2025-03-31 0000730464 atge:TuitionMember 2024-07-01 2025-03-31 0000730464 atge:OtherServicesMember 2024-07-01 2025-03-31 0000730464 atge:DomesticOperationsMember 2024-07-01 2025-03-31 0000730464 atge:ChamberlainUniversitySegmentMember 2024-07-01 2025-03-31 0000730464 atge:BarbadosSt.KittsAndSt.MaartenMember 2024-07-01 2025-03-31 0000730464 atge:TuitionMember atge:WaldenUniversitySegmentMember 2024-01-01 2024-03-31 0000730464 atge:TuitionMember atge:MedicalAndVeterinaryMember 2024-01-01 2024-03-31 0000730464 atge:TuitionMember atge:ChamberlainUniversitySegmentMember 2024-01-01 2024-03-31 0000730464 atge:OtherServicesMember atge:WaldenUniversitySegmentMember 2024-01-01 2024-03-31 0000730464 atge:OtherServicesMember atge:MedicalAndVeterinaryMember 2024-01-01 2024-03-31 0000730464 atge:OtherServicesMember atge:ChamberlainUniversitySegmentMember 2024-01-01 2024-03-31 0000730464 atge:WaldenUniversitySegmentMember 2024-01-01 2024-03-31 0000730464 atge:TuitionMember 2024-01-01 2024-03-31 0000730464 atge:OtherServicesMember 2024-01-01 2024-03-31 0000730464 atge:DomesticOperationsMember 2024-01-01 2024-03-31 0000730464 atge:ChamberlainUniversitySegmentMember 2024-01-01 2024-03-31 0000730464 atge:BarbadosSt.KittsAndSt.MaartenMember 2024-01-01 2024-03-31 0000730464 atge:TuitionMember atge:WaldenUniversitySegmentMember 2023-07-01 2024-03-31 0000730464 atge:TuitionMember atge:MedicalAndVeterinaryMember 2023-07-01 2024-03-31 0000730464 atge:TuitionMember atge:ChamberlainUniversitySegmentMember 2023-07-01 2024-03-31 0000730464 atge:OtherServicesMember atge:WaldenUniversitySegmentMember 2023-07-01 2024-03-31 0000730464 atge:OtherServicesMember atge:MedicalAndVeterinaryMember 2023-07-01 2024-03-31 0000730464 atge:OtherServicesMember atge:ChamberlainUniversitySegmentMember 2023-07-01 2024-03-31 0000730464 atge:TuitionMember 2023-07-01 2024-03-31 0000730464 atge:OtherServicesMember 2023-07-01 2024-03-31 0000730464 atge:DomesticOperationsMember 2023-07-01 2024-03-31 0000730464 atge:ChamberlainUniversitySegmentMember 2023-07-01 2024-03-31 0000730464 atge:BarbadosSt.KittsAndSt.MaartenMember 2023-07-01 2024-03-31 0000730464 us-gaap:RealEstateOtherMember us-gaap:CorporateMember 2025-01-01 2025-03-31 0000730464 us-gaap:RealEstateOtherMember atge:MedicalAndVeterinaryMember 2025-01-01 2025-03-31 0000730464 us-gaap:EmployeeSeveranceMember us-gaap:CorporateMember 2025-01-01 2025-03-31 0000730464 us-gaap:EmployeeSeveranceMember atge:MedicalAndVeterinaryMember 2025-01-01 2025-03-31 0000730464 us-gaap:EmployeeSeveranceMember atge:ChamberlainUniversityMember 2025-01-01 2025-03-31 0000730464 us-gaap:RealEstateOtherMember 2025-01-01 2025-03-31 0000730464 us-gaap:EmployeeSeveranceMember 2025-01-01 2025-03-31 0000730464 us-gaap:CorporateMember 2025-01-01 2025-03-31 0000730464 atge:MedicalAndVeterinaryMember 2025-01-01 2025-03-31 0000730464 atge:ChamberlainUniversityMember 2025-01-01 2025-03-31 0000730464 us-gaap:RealEstateOtherMember us-gaap:CorporateMember 2024-07-01 2025-03-31 0000730464 us-gaap:RealEstateOtherMember atge:MedicalAndVeterinaryMember 2024-07-01 2025-03-31 0000730464 us-gaap:RealEstateOtherMember atge:ChamberlainUniversityMember 2024-07-01 2025-03-31 0000730464 us-gaap:EmployeeSeveranceMember us-gaap:CorporateMember 2024-07-01 2025-03-31 0000730464 us-gaap:EmployeeSeveranceMember atge:MedicalAndVeterinaryMember 2024-07-01 2025-03-31 0000730464 us-gaap:EmployeeSeveranceMember atge:ChamberlainUniversityMember 2024-07-01 2025-03-31 0000730464 us-gaap:RealEstateOtherMember 2024-07-01 2025-03-31 0000730464 us-gaap:EmployeeSeveranceMember 2024-07-01 2025-03-31 0000730464 us-gaap:CorporateMember 2024-07-01 2025-03-31 0000730464 atge:MedicalAndVeterinaryMember 2024-07-01 2025-03-31 0000730464 atge:ChamberlainUniversityMember 2024-07-01 2025-03-31 0000730464 us-gaap:RealEstateOtherMember us-gaap:CorporateMember 2024-01-01 2024-03-31 0000730464 us-gaap:RealEstateOtherMember atge:MedicalAndVeterinaryMember 2024-01-01 2024-03-31 0000730464 us-gaap:RealEstateOtherMember 2024-01-01 2024-03-31 0000730464 us-gaap:CorporateMember 2024-01-01 2024-03-31 0000730464 atge:MedicalAndVeterinaryMember 2024-01-01 2024-03-31 0000730464 us-gaap:RealEstateOtherMember us-gaap:CorporateMember 2023-07-01 2024-03-31 0000730464 us-gaap:RealEstateOtherMember atge:WaldenUniversitySegmentMember 2023-07-01 2024-03-31 0000730464 us-gaap:RealEstateOtherMember atge:MedicalAndVeterinaryMember 2023-07-01 2024-03-31 0000730464 us-gaap:EmployeeSeveranceMember atge:MedicalAndVeterinaryMember 2023-07-01 2024-03-31 0000730464 us-gaap:RealEstateOtherMember 2023-07-01 2024-03-31 0000730464 us-gaap:EmployeeSeveranceMember 2023-07-01 2024-03-31 0000730464 us-gaap:CorporateMember 2023-07-01 2024-03-31 0000730464 atge:WaldenUniversitySegmentMember 2023-07-01 2024-03-31 0000730464 atge:MedicalAndVeterinaryMember 2023-07-01 2024-03-31 0000730464 atge:TermLoanMember 2025-01-17 2025-01-17 0000730464 atge:TermLoanMember 2022-11-22 2022-11-22 0000730464 atge:TermLoanMember 2022-09-22 2022-09-22 0000730464 atge:TermLoanMember 2022-03-11 2022-03-11 0000730464 srt:MinimumMember 2024-07-01 2025-03-31 0000730464 srt:MaximumMember 2024-07-01 2025-03-31 0000730464 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-03-31 0000730464 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2025-03-31 0000730464 srt:MinimumMember us-gaap:BuildingImprovementsMember 2025-03-31 0000730464 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-03-31 0000730464 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2025-03-31 0000730464 srt:MaximumMember us-gaap:BuildingImprovementsMember 2025-03-31 0000730464 srt:MinimumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0000730464 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2024-06-30 0000730464 srt:MinimumMember us-gaap:BuildingImprovementsMember 2024-06-30 0000730464 srt:MaximumMember us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0000730464 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2024-06-30 0000730464 srt:MaximumMember us-gaap:BuildingImprovementsMember 2024-06-30 0000730464 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2025-03-31 0000730464 us-gaap:LeaseholdImprovementsMember 2025-03-31 0000730464 us-gaap:LandMember 2025-03-31 0000730464 us-gaap:FurnitureAndFixturesMember 2025-03-31 0000730464 us-gaap:ConstructionInProgressMember 2025-03-31 0000730464 us-gaap:BuildingImprovementsMember 2025-03-31 0000730464 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-06-30 0000730464 us-gaap:LeaseholdImprovementsMember 2024-06-30 0000730464 us-gaap:LandMember 2024-06-30 0000730464 us-gaap:FurnitureAndFixturesMember 2024-06-30 0000730464 us-gaap:ConstructionInProgressMember 2024-06-30 0000730464 us-gaap:BuildingImprovementsMember 2024-06-30 0000730464 atge:AljanalCarrollClaudiaProvostCharlesTiffanyFairCaseMember 2024-11-27 2024-11-27 0000730464 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000730464 us-gaap:RetainedEarningsMember 2024-07-01 2025-03-31 0000730464 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000730464 us-gaap:RetainedEarningsMember 2023-07-01 2024-03-31 0000730464 atge:AljanalCarrollClaudiaProvostCharlesTiffanyFairCaseMember 2024-06-30 0000730464 atge:TermLoanMember us-gaap:FairValueInputsLevel2Member 2025-03-31 0000730464 atge:SeniorSecuredNotesDue2028Member us-gaap:FairValueInputsLevel1Member 2025-03-31 0000730464 atge:TermLoanMember us-gaap:FairValueInputsLevel2Member 2024-06-30 0000730464 atge:SeniorSecuredNotesDue2028Member us-gaap:FairValueInputsLevel1Member 2024-06-30 0000730464 us-gaap:AccountsReceivableMember atge:CreditExtensionProgramMember 2025-03-31 0000730464 us-gaap:AccountsReceivableMember atge:CreditExtensionProgramMember 2024-06-30 0000730464 atge:AljanalCarrollClaudiaProvostCharlesTiffanyFairCaseMember 2023-09-21 2023-09-21 0000730464 atge:MembershipInterestPurchaseAgreementWithLaureateEducationInc.Member 2024-11-01 2024-11-30 0000730464 us-gaap:RevolvingCreditFacilityMember 2021-08-12 0000730464 us-gaap:RevolvingCreditFacilityMember 2024-03-31 0000730464 us-gaap:LetterOfCreditMember atge:TitleIvLetterOfCreditMember 2025-03-31 0000730464 atge:SuretyBackedLetterOfCreditMember atge:TitleIvLetterOfCreditMember 2025-02-28 0000730464 us-gaap:RevolvingCreditFacilityMember atge:TitleIvLetterOfCreditMember 2025-01-31 0000730464 us-gaap:RevolvingCreditFacilityMember atge:TitleIvLetterOfCreditMember 2024-12-13 0000730464 atge:SuretyBackedLetterOfCreditMember atge:TitleIvLetterOfCreditMember 2024-12-13 0000730464 us-gaap:LetterOfCreditMember atge:TitleIvLetterOfCreditMember 2024-12-03 0000730464 atge:TitleIvLetterOfCreditMember 2023-11-01 0000730464 us-gaap:InterestExpenseMember atge:NonqualifiedDeferredCompensationPlanMember 2025-03-31 0000730464 us-gaap:InterestExpenseMember atge:NonqualifiedDeferredCompensationPlanMember 2024-06-30 0000730464 us-gaap:LetterOfCreditMember 2025-01-01 2025-03-31 0000730464 atge:TermLoanMember 2025-01-01 2025-03-31 0000730464 atge:SeniorSecuredNotesDue2028Member 2025-01-01 2025-03-31 0000730464 us-gaap:LetterOfCreditMember 2024-07-01 2025-03-31 0000730464 us-gaap:LetterOfCreditMember 2024-01-01 2024-03-31 0000730464 atge:TermLoanMember 2024-01-01 2024-03-31 0000730464 atge:SeniorSecuredNotesDue2028Member 2024-01-01 2024-03-31 0000730464 us-gaap:LetterOfCreditMember 2023-07-01 2024-03-31 0000730464 atge:TermLoanMember 2023-07-01 2024-03-31 0000730464 atge:SeniorSecuredNotesDue2028Member 2023-07-01 2024-03-31 0000730464 us-gaap:TradeNamesMember 2025-03-31 0000730464 atge:TitleFourEligibilityAndAccreditationsMember 2025-03-31 0000730464 us-gaap:TradeNamesMember 2024-06-30 0000730464 atge:TitleFourEligibilityAndAccreditationsMember 2024-06-30 0000730464 us-gaap:SuretyBondMember 2025-03-31 0000730464 atge:MedicalAndVeterinaryMember 2025-03-31 0000730464 atge:ChamberlainUniversitySegmentMember 2025-03-31 0000730464 atge:WaldenUniversitySegmentMember 2024-06-30 0000730464 atge:MedicalAndVeterinaryMember 2024-06-30 0000730464 atge:ChamberlainUniversitySegmentMember 2024-06-30 0000730464 atge:WaldenUniversitySegmentMember 2025-03-31 0000730464 atge:CurriculumMember 2025-03-31 0000730464 atge:CurriculumMember 2024-06-30 0000730464 us-gaap:FinancialAssetPastDueMember 2025-03-31 0000730464 atge:FinancingReceivablesGreaterThan150DaysPastDueMember 2025-03-31 0000730464 atge:FinancingReceivables91To120DaysPastDueMember 2025-03-31 0000730464 atge:FinancingReceivables61To90DaysPastDueMember 2025-03-31 0000730464 atge:FinancingReceivables31To60DaysPastDueMember 2025-03-31 0000730464 atge:FinancingReceivables1To30DaysPastDueMember 2025-03-31 0000730464 atge:FinancingReceivables121To150DaysPastDueMember 2025-03-31 0000730464 atge:FinancingReceivableGrossMember 2025-03-31 0000730464 atge:FinancingReceivableCurrentMember 2025-03-31 0000730464 us-gaap:FinancialAssetPastDueMember 2024-06-30 0000730464 atge:FinancingReceivablesGreaterThan150DaysPastDueMember 2024-06-30 0000730464 atge:FinancingReceivables91To120DaysPastDueMember 2024-06-30 0000730464 atge:FinancingReceivables61To90DaysPastDueMember 2024-06-30 0000730464 atge:FinancingReceivables31To60DaysPastDueMember 2024-06-30 0000730464 atge:FinancingReceivables1To30DaysPastDueMember 2024-06-30 0000730464 atge:FinancingReceivables121To150DaysPastDueMember 2024-06-30 0000730464 atge:FinancingReceivableGrossMember 2024-06-30 0000730464 atge:FinancingReceivableCurrentMember 2024-06-30 0000730464 us-gaap:StockOptionMember 2024-07-01 2025-03-31 0000730464 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2025-03-31 0000730464 us-gaap:PerformanceSharesMember 2024-07-01 2025-03-31 0000730464 us-gaap:StockOptionMember 2025-03-31 0000730464 us-gaap:RestrictedStockUnitsRSUMember 2025-03-31 0000730464 us-gaap:PerformanceSharesMember 2025-03-31 0000730464 2023-07-01 2024-06-30 0000730464 srt:MaximumMember atge:DevryUniversityMember 2017-12-04 0000730464 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember atge:NonqualifiedDeferredCompensationPlanMember 2025-03-31 0000730464 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember atge:NonqualifiedDeferredCompensationPlanMember 2024-06-30 0000730464 us-gaap:RevolvingCreditFacilityMember 2025-03-31 0000730464 us-gaap:RevolvingCreditFacilityMember 2024-06-30 0000730464 atge:SeniorSecuredNotesDue2028Member 2022-07-01 2022-09-30 0000730464 atge:SeniorSecuredNotesDue2028Member 2022-06-01 2022-06-30 0000730464 atge:SeniorSecuredNotesDue2028Member 2022-04-11 2022-04-11 0000730464 atge:SeniorSecuredNotesDue2028Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2021-03-01 2021-03-01 0000730464 atge:SeniorSecuredNotesDue2028Member us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2021-03-01 2021-03-01 0000730464 atge:SeniorSecuredNotesDue2028Member us-gaap:DebtInstrumentRedemptionPeriodOneMember 2021-03-01 2021-03-01 0000730464 atge:TermLoanMember 2022-01-01 2022-03-31 0000730464 atge:TermLoanMember 2024-08-21 2024-08-21 0000730464 atge:TermLoanMember 2024-01-26 2024-01-26 0000730464 atge:TermLoanMember 2021-08-12 0000730464 atge:SeniorSecuredNotesDue2028Member 2021-03-01 0000730464 atge:TermLoanMember 2025-03-31 0000730464 atge:SeniorSecuredNotesDue2028Member 2025-03-31 0000730464 atge:TermLoanMember 2024-06-30 0000730464 atge:SeniorSecuredNotesDue2028Member 2024-06-30 0000730464 atge:TermLoanMember atge:AlternateBaseRateMember 2024-08-21 2024-08-21 0000730464 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-01 2025-03-31 0000730464 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember atge:AlternateBaseRateMember 2024-07-01 2025-03-31 0000730464 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-01 2025-03-31 0000730464 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember atge:AlternateBaseRateMember 2024-07-01 2025-03-31 0000730464 srt:MinimumMember atge:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-26 2024-01-26 0000730464 srt:MinimumMember atge:TermLoanMember atge:AlternateBaseRateMember 2024-01-26 2024-01-26 0000730464 srt:MaximumMember atge:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-26 2024-01-26 0000730464 srt:MaximumMember atge:TermLoanMember atge:AlternateBaseRateMember 2024-01-26 2024-01-26 0000730464 srt:MinimumMember atge:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-25 2024-01-25 0000730464 srt:MinimumMember atge:TermLoanMember atge:AlternateBaseRateMember 2024-01-25 2024-01-25 0000730464 srt:MaximumMember atge:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-25 2024-01-25 0000730464 srt:MaximumMember atge:TermLoanMember atge:AlternateBaseRateMember 2024-01-25 2024-01-25 0000730464 us-gaap:OtherNoncurrentLiabilitiesMember 2025-03-31 0000730464 us-gaap:OtherNoncurrentLiabilitiesMember 2024-06-30 0000730464 atge:DeferredRevenueCurrentMember 2025-03-31 0000730464 atge:DeferredRevenueCurrentMember 2024-06-30 0000730464 us-gaap:CommonStockMember 2025-03-31 0000730464 us-gaap:CommonStockMember 2024-12-31 0000730464 us-gaap:CommonStockMember 2024-06-30 0000730464 us-gaap:CommonStockMember 2024-03-31 0000730464 us-gaap:CommonStockMember 2023-12-31 0000730464 us-gaap:CommonStockMember 2023-06-30 0000730464 us-gaap:StockCompensationPlanMember 2025-03-31 0000730464 srt:ScenarioPreviouslyReportedMember 2023-07-01 2024-03-31 0000730464 atge:WaldenUniversityLlcMember 2025-01-01 2025-03-31 0000730464 atge:WaldenUniversityLlcMember 2024-07-01 2025-03-31 0000730464 atge:WaldenUniversityLlcMember 2024-01-01 2024-03-31 0000730464 atge:WaldenUniversityLlcMember 2023-07-01 2024-03-31 0000730464 us-gaap:FairValueInputsLevel3Member us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-01-01 2025-03-31 0000730464 us-gaap:FairValueInputsLevel3Member us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2025-03-31 0000730464 srt:WeightedAverageMember 2025-01-01 2025-03-31 0000730464 srt:WeightedAverageMember 2024-07-01 2025-03-31 0000730464 srt:WeightedAverageMember 2024-01-01 2024-03-31 0000730464 srt:WeightedAverageMember 2023-07-01 2024-03-31 0000730464 atge:TermLoanMember 2024-07-01 2025-03-31 0000730464 atge:SeniorSecuredNotesDue2028Member 2024-07-01 2025-03-31 0000730464 2024-12-31 0000730464 2024-03-31 0000730464 2023-06-30 0000730464 srt:MaximumMember atge:AuthorizedOnMayTwoThousandTwentyFiveMember us-gaap:SubsequentEventMember 2025-05-06 0000730464 srt:MaximumMember atge:AuthorizedOnJanuaryNineteenTwoThousandTwentyFourMember 2024-01-19 0000730464 srt:MaximumMember atge:AuthorizedOnMarchOneTwoThousandTwentyTwoMember 2022-03-01 0000730464 2025-05-05 0000730464 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000730464 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2025-03-31 0000730464 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000730464 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2024-03-31 0000730464 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000730464 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000730464 us-gaap:TreasuryStockCommonMember 2024-07-01 2025-03-31 0000730464 us-gaap:CommonStockMember 2024-07-01 2025-03-31 0000730464 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0000730464 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000730464 us-gaap:TreasuryStockCommonMember 2023-07-01 2024-03-31 0000730464 us-gaap:CommonStockMember 2023-07-01 2024-03-31 0000730464 atge:SeniorSecuredNotesDue2028Member 2021-03-01 2021-03-01 0000730464 us-gaap:LetterOfCreditMember atge:TitleIvLetterOfCreditMember 2024-12-03 2024-12-03 0000730464 atge:TitleIvLetterOfCreditMember 2023-11-01 2023-11-01 0000730464 us-gaap:OperatingSegmentsMember atge:WaldenUniversitySegmentMember 2025-01-01 2025-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:MedicalAndVeterinaryMember 2025-01-01 2025-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:ChamberlainUniversitySegmentMember 2025-01-01 2025-03-31 0000730464 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:WaldenUniversitySegmentMember 2024-07-01 2025-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:MedicalAndVeterinaryMember 2024-07-01 2025-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:ChamberlainUniversitySegmentMember 2024-07-01 2025-03-31 0000730464 us-gaap:CorporateNonSegmentMember 2024-07-01 2025-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:WaldenUniversitySegmentMember 2024-01-01 2024-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:MedicalAndVeterinaryMember 2024-01-01 2024-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:ChamberlainUniversitySegmentMember 2024-01-01 2024-03-31 0000730464 us-gaap:CorporateNonSegmentMember 2024-01-01 2024-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:WaldenUniversitySegmentMember 2023-07-01 2024-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:MedicalAndVeterinaryMember 2023-07-01 2024-03-31 0000730464 us-gaap:OperatingSegmentsMember atge:ChamberlainUniversitySegmentMember 2023-07-01 2024-03-31 0000730464 us-gaap:CorporateNonSegmentMember 2023-07-01 2024-03-31 0000730464 2023-12-31 0000730464 atge:WaldenTitleIvLetterOfCreditMember 2024-12-06 0000730464 srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember 2023-07-01 2024-03-31 0000730464 atge:DevryUniversityMember 2018-12-01 2018-12-11 0000730464 2024-10-01 2024-12-31 0000730464 2023-10-01 2023-12-31 0000730464 2021-10-01 2025-03-31 0000730464 us-gaap:AccruedLiabilitiesMember atge:NonqualifiedDeferredCompensationPlanMember 2025-03-31 0000730464 us-gaap:AccruedLiabilitiesMember atge:NonqualifiedDeferredCompensationPlanMember 2024-06-30 0000730464 us-gaap:RevolvingCreditFacilityMember 2024-07-01 2025-03-31 0000730464 atge:SeniorSecuredNotesDue2028AndTermBLoanMember 2024-07-01 2025-03-31 0000730464 atge:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-08-21 2024-08-21 0000730464 us-gaap:RevolvingCreditFacilityMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-07-01 2025-03-31 0000730464 atge:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-26 2024-01-26 0000730464 atge:TermLoanMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-25 2024-01-25 0000730464 atge:TermLoanMember 2021-08-12 2021-08-12 0000730464 srt:MaximumMember atge:SeniorSecuredNotesDue2028AndTermBLoanMember 2024-07-01 2025-03-31 0000730464 us-gaap:AccruedLiabilitiesMember atge:SeniorSecuredNotesDue2028Member 2025-03-31 0000730464 us-gaap:AccruedLiabilitiesMember atge:SeniorSecuredNotesDue2028Member 2024-06-30 0000730464 atge:WaldenUniversitySegmentMember 2022-06-23 2022-11-15 0000730464 atge:RossUniversitySchoolOfVeterinaryMedicineReportingUnitMember 2022-06-23 2022-11-15 0000730464 atge:RossUniversitySchoolOfMedicineReportingUnitMember 2022-06-23 2022-11-15 0000730464 atge:ChamberlainUniversitySegmentMember 2022-06-23 2022-11-15 0000730464 2025-03-31 0000730464 2024-06-30 0000730464 2025-01-01 2025-03-31 0000730464 2024-07-01 2025-03-31 0000730464 2024-01-01 2024-03-31 0000730464 2023-07-01 2024-03-31 iso4217:USD atge:item xbrli:pure atge:location xbrli:shares iso4217:USD xbrli:shares atge:segment

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

​ ​ ​ |
(Mark One)
☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| For the quarterly period ended March 31, 2025
| or
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| For the transition period from _____ to _____
| Commission File Number: 001-13988

Adtalem Global Education Inc.

(Exact name of registrant as specified in its charter)

Delaware | 36-3150143
(State or other jurisdiction of | (I.R.S. Employer
incorporation or organization) | Identification No.)
233 South Wacker Drive |
Chicago, Illinois | 60606
(Address of principal executive offices) | (Zip Code)

(312) 651-1400

(Registrant’s telephone number; including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, $0.01 par value per share | ATGE | New York Stock Exchange
Common stock, $0.01 par value per share | ATGE | NYSE Texas

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| ​ |  |  |
Large accelerated filer | þ |  | Accelerated filer | ☐
Non-accelerated filer | ◻ |  | Smaller reporting company | ☐
| ​ |  | Emerging growth company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

As of May 5, 2025, there were 35,927,962 shares of the registrant’s common stock, $0.01 par value per share outstanding.

​

​

​

​

Table of Contents

Adtalem Global Education Inc.

Form 10-Q

Table of Contents

​

|  | Page
​ | Part I. Financial Information | ​
Item 1. | Financial Statements | 1
​ | Consolidated Balance Sheets | 1
​ | Consolidated Statements of Income | 2
​ | Consolidated Statements of Cash Flows | 3
​ | Consolidated Statements of Shareholders’ Equity | 4
​ | Notes to Consolidated Financial Statements | 5
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 27
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 44
Item 4. | Controls and Procedures | 44
​ | Part II. Other Information | ​
Item 1. | Legal Proceedings | 44
Item 1A. | Risk Factors | 44
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 44
Item 5. | Other Information | 45
Item 6. | Exhibits | 45
| Signature | 46

​

​

​

​

Table of Contents

Part I. Financial Information

Item 1. Financial Statements

​

Adtalem Global Education Inc.

Consolidated Balance Sheets

(unaudited)

(in thousands, except par value)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | June 30,
​ | ​ | 2025 | ​ | 2024
Assets: | ​ | ​ | ​ | ​ | ​ | ​
Current assets: | ​ | ​ | ​ | ​ | ​ | ​
Cash and cash equivalents | ​ | $ | 219,017 | ​ | $ | 219,306
Restricted cash | ​ |  | 2,164 | ​ |  | 1,896
Accounts and financing receivables, net | ​ |  | 162,972 | ​ |  | 126,833
Prepaid expenses and other current assets | ​ |  | 66,190 | ​ |  | 70,050
Total current assets | ​ |  | 450,343 | ​ |  | 418,085
Noncurrent assets: | ​ |  | ​ | ​ |  | ​
Property and equipment, net | ​ | ​ | 250,764 | ​ | ​ | 248,524
Operating lease assets | ​ |  | 198,465 | ​ |  | 176,755
Deferred income taxes | ​ |  | 33,157 | ​ |  | 49,088
Intangible assets, net | ​ |  | 768,279 | ​ |  | 776,694
Goodwill | ​ |  | 961,262 | ​ |  | 961,262
Other assets, net | ​ |  | 119,664 | ​ |  | 103,184
Assets held for sale | ​ | ​ | 7,825 | ​ | ​ | 7,825
Total noncurrent assets | ​ |  | 2,339,416 | ​ |  | 2,323,332
Total assets | ​ | $ | 2,789,759 | ​ | $ | 2,741,417
Liabilities and shareholders' equity: | ​ |  | ​ | ​ | ​ | ​
Current liabilities: | ​ |  | ​ | ​ | ​ | ​
Accounts payable | ​ | $ | 98,709 | ​ | $ | 102,626
Accrued payroll and benefits | ​ |  | 72,676 | ​ |  | 71,373
Accrued liabilities | ​ |  | 86,491 | ​ |  | 96,957
Deferred revenue | ​ |  | 247,811 | ​ |  | 185,272
Current operating lease liabilities | ​ |  | 34,882 | ​ |  | 31,429
Total current liabilities | ​ |  | 540,569 | ​ |  | 487,657
Noncurrent liabilities: | ​ |  | ​ | ​ |  | ​
Long-term debt | ​ |  | 552,186 | ​ |  | 648,712
Long-term operating lease liabilities | ​ |  | 193,460 | ​ |  | 167,712
Deferred income taxes | ​ |  | 33,589 | ​ |  | 29,526
Other liabilities | ​ |  | 37,242 | ​ |  | 38,675
Total noncurrent liabilities | ​ |  | 816,477 | ​ |  | 884,625
Total liabilities | ​ |  | 1,357,046 | ​ |  | 1,372,282
Commitments and contingencies | ​ |  | ​ | ​ |  | ​
Shareholders' equity: | ​ |  | ​ | ​ |  | ​
Common stock, $0.01 par value per share, 200,000 shares authorized; 36,512 and 37,681 shares outstanding as of March 31, 2025 and June 30, 2024, respectively | ​ |  | 839 | ​ |  | 832
Additional paid-in capital | ​ |  | 653,635 | ​ |  | 611,949
Retained earnings | ​ |  | 2,723,362 | ​ |  | 2,540,509
Accumulated other comprehensive loss | ​ |  | (2,227) | ​ |  | (2,227)
Treasury stock, at cost, 47,387 and 45,513 shares as of March 31, 2025 and June 30, 2024, respectively | ​ |  | (1,942,896) | ​ |  | (1,781,928)
Total shareholders' equity | ​ |  | 1,432,713 | ​ |  | 1,369,135
Total liabilities and shareholders' equity | ​ | $ | 2,789,759 | ​ | $ | 2,741,417

​

See accompanying Notes to Consolidated Financial Statements.

​

1

Table of Contents

Adtalem Global Education Inc.

Consolidated Statements of Income

(unaudited)

(in thousands, except per share data)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Revenue | ​ | $ | 466,055 | ​ | $ | 412,658 | ​ | $ | 1,331,184 | ​ | $ | 1,174,745
Operating cost and expense: | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​
Cost of educational services | ​ |  | 199,869 | ​ |  | 175,321 | ​ |  | 572,500 | ​ |  | 516,008
Student services and administrative expense | ​ |  | 175,167 | ​ |  | 156,689 | ​ |  | 491,141 | ​ |  | 478,368
Restructuring expense | ​ |  | 510 | ​ |  | 473 | ​ |  | 2,926 | ​ |  | 1,217
Business integration expense | ​ |  | — | ​ |  | 18,450 | ​ |  | — | ​ |  | 30,621
Total operating cost and expense | ​ |  | 375,546 | ​ |  | 350,933 | ​ |  | 1,066,567 | ​ |  | 1,026,214
Operating income | ​ |  | 90,509 | ​ |  | 61,725 | ​ |  | 264,617 | ​ |  | 148,531
Interest expense | ​ |  | (13,074) | ​ |  | (16,560) | ​ |  | (41,465) | ​ |  | (48,910)
Other income, net | ​ |  | 1,898 | ​ |  | 2,871 | ​ |  | 6,779 | ​ |  | 8,648
Income from continuing operations before income taxes | ​ |  | 79,333 | ​ |  | 48,036 | ​ |  | 229,931 | ​ |  | 108,269
Provision for income taxes | ​ |  | (18,539) | ​ |  | (10,595) | ​ |  | (51,716) | ​ |  | (21,156)
Income from continuing operations | ​ |  | 60,794 | ​ |  | 37,441 | ​ |  | 178,215 | ​ |  | 87,113
Discontinued operations: | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​
Income (loss) from discontinued operations before income taxes | ​ |  | 52 | ​ |  | (832) | ​ |  | 6,216 | ​ |  | 329
(Provision for) benefit from income taxes | ​ |  | (14) | ​ |  | 212 | ​ |  | (1,578) | ​ |  | (84)
Income (loss) from discontinued operations | ​ |  | 38 | ​ |  | (620) | ​ |  | 4,638 | ​ |  | 245
Net income and comprehensive income | ​ | $ | 60,832 | ​ | $ | 36,821 | ​ | $ | 182,853 | ​ | $ | 87,358
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Earnings (loss) per share: | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​
Basic: | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​
Continuing operations | ​ | $ | 1.64 | ​ | $ | 0.97 | ​ | $ | 4.76 | ​ | $ | 2.18
Discontinued operations | ​ | $ | 0.00 | ​ | $ | (0.02) | ​ | $ | 0.12 | ​ | $ | 0.01
Total basic earnings per share | ​ | $ | 1.64 | ​ | $ | 0.95 | ​ | $ | 4.88 | ​ | $ | 2.18
Diluted: | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
Continuing operations | ​ | $ | 1.59 | ​ | $ | 0.94 | ​ | $ | 4.62 | ​ | $ | 2.13
Discontinued operations | ​ | $ | 0.00 | ​ | $ | (0.02) | ​ | $ | 0.12 | ​ | $ | 0.01
Total diluted earnings per share | ​ | $ | 1.59 | ​ | $ | 0.93 | ​ | $ | 4.74 | ​ | $ | 2.14
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average shares outstanding: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic shares | ​ | ​ | 37,140 | ​ | ​ | 38,713 | ​ | ​ | 37,434 | ​ | ​ | 40,000
Diluted shares | ​ | ​ | 38,233 | ​ | ​ | 39,636 | ​ | ​ | 38,583 | ​ | ​ | 40,874

​

See accompanying Notes to Consolidated Financial Statements.

​

2

Table of Contents

Adtalem Global Education Inc.

Consolidated Statements of Cash Flows

(unaudited)

(in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended
​ | ​ | March 31,
​ | ​ | 2025 | ​ | 2024
Operating activities: | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | $ | 182,853 | ​ | $ | 87,358
Income from discontinued operations | ​ |  | (4,638) | ​ |  | (245)
Income from continuing operations | ​ | ​ | 178,215 | ​ | ​ | 87,113
Adjustments to reconcile net income to net cash provided by operating activities: | ​ |  | ​ | ​ |  | ​
Stock-based compensation | ​ |  | 31,181 | ​ |  | 19,405
Amortization and impairments to operating lease assets | ​ | ​ | 25,330 | ​ | ​ | 24,705
Depreciation | ​ |  | 30,267 | ​ |  | 29,879
Amortization of acquired intangible assets | ​ |  | 8,415 | ​ |  | 28,296
Amortization of debt discount and issuance costs | ​ | ​ | 4,995 | ​ | ​ | 4,550
Provision for bad debts | ​ | ​ | 46,854 | ​ | ​ | 35,741
Deferred income taxes | ​ |  | 19,994 | ​ |  | (4,650)
Loss on disposals and impairments of property and equipment | ​ |  | 2,522 | ​ |  | 50
Gain on investments | ​ | ​ | (268) | ​ | ​ | (1,281)
Unrealized loss on assets held for sale | ​ | ​ | — | ​ | ​ | 647
Changes in assets and liabilities: | ​ |  | ​ | ​ |  | ​
Accounts and financing receivables | ​ |  | (80,613) | ​ |  | (73,661)
Prepaid expenses and other current assets | ​ |  | 5,727 | ​ |  | (2,484)
Cloud computing implementation assets | ​ |  | (21,959) | ​ |  | (19,262)
Accounts payable | ​ |  | (9,978) | ​ |  | 12,632
Accrued payroll and benefits | ​ | ​ | 1,406 | ​ | ​ | 15,671
Accrued liabilities | ​ |  | (10,449) | ​ |  | 39,748
Deferred revenue | ​ |  | 66,081 | ​ |  | 60,935
Operating lease liabilities | ​ | ​ | (17,839) | ​ | ​ | (28,448)
Other assets and liabilities | ​ |  | (6,068) | ​ |  | (2,475)
Net cash provided by operating activities-continuing operations | ​ |  | 273,813 | ​ |  | 227,111
Net cash provided by operating activities-discontinued operations | ​ |  | 4,394 | ​ |  | 8,396
Net cash provided by operating activities | ​ |  | 278,207 | ​ |  | 235,507
Investing activities: | ​ |  | ​ | ​ | ​ | ​
Capital expenditures | ​ |  | (31,337) | ​ |  | (32,316)
Proceeds from sales of marketable securities | ​ |  | 3,120 | ​ |  | 626
Purchases of marketable securities | ​ |  | (2,048) | ​ |  | (498)
Net cash used in investing activities | ​ |  | (30,265) | ​ |  | (32,188)
Financing activities: | ​ |  | ​ | ​ | ​ | ​
Proceeds from exercise of stock options | ​ |  | 10,008 | ​ |  | 15,412
Employee taxes paid on withholding shares | ​ |  | (12,457) | ​ |  | (6,600)
Proceeds from stock issued under Colleague Stock Purchase Plan | ​ |  | 922 | ​ |  | 581
Repurchases of common stock for treasury | ​ |  | (146,436) | ​ |  | (250,463)
Proceeds from issuance of long-term debt | ​ |  | 9,873 | ​ |  | 1,896
Repayments of long-term debt | ​ |  | (109,873) | ​ |  | (51,896)
Net cash used in financing activities | ​ |  | (247,963) | ​ |  | (291,070)
Net decrease in cash, cash equivalents and restricted cash | ​ |  | (21) | ​ |  | (87,751)
Cash, cash equivalents and restricted cash at beginning of period | ​ |  | 221,202 | ​ |  | 275,075
Cash, cash equivalents and restricted cash at end of period | ​ | $ | 221,181 | ​ | $ | 187,324
Non-cash investing and financing activities: | ​ | ​ | ​ | ​ | ​ | ​
Accrued capital expenditures | ​ | $ | 12,410 | ​ | $ | 6,217
Accrued liability for repurchases of common stock | ​ | $ | 4,879 | ​ | $ | 2,995
Accrued excise tax on share repurchases | ​ | $ | 1,055 | ​ | $ | 3,257

​

See accompanying Notes to Consolidated Financial Statements.

​

3

Table of Contents

Adtalem Global Education Inc.

Consolidated Statements of Shareholders’ Equity

(unaudited)

(in thousands)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Accumulated | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Additional | ​ | ​ | ​ | ​ | Other | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Common Stock | ​ | Paid-In | ​ | Retained | ​ | Comprehensive | ​ | Treasury Stock | ​ | ​ | ​
​ | ​ | Shares | ​ | Amount | ​ | Capital | ​ | Earnings | ​ | Loss | ​ | Shares | ​ | Amount | ​ | Total
December 31, 2023 | ​ | ​ | 83,092 | ​ | $ | 831 | ​ | $ | 597,587 | ​ | $ | 2,454,269 | ​ | $ | (2,227) | ​ | ​ | 43,566 | ​ | $ | (1,681,061) | ​ | $ | 1,369,399
Net income |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | 36,821 |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | 36,821
Stock-based compensation |  | ​ | ​ |  | ​ | ​ |  | ​ | 5,900 |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | 5,900
Net activity from stock-based compensation awards |  | ​ | 8 |  | ​ | ​ |  | ​ | 98 |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2 |  | ​ | (95) |  | ​ | 3
Proceeds from stock issued under Colleague Stock Purchase Plan | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 86 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (5) | ​ | ​ | 162 | ​ | ​ | 248
Repurchases of common stock for treasury | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,772 | ​ | ​ | (91,408) | ​ | ​ | (91,408)
March 31, 2024 | ​ | ​ | 83,100 | ​ | $ | 831 | ​ | $ | 603,671 | ​ | $ | 2,491,090 | ​ | $ | (2,227) | ​ | ​ | 45,335 | ​ | $ | (1,772,402) | ​ | $ | 1,320,963
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
December 31, 2024 | ​ | ​ | 83,886 | ​ | $ | 839 | ​ | $ | 642,975 | ​ | $ | 2,662,530 | ​ | $ | (2,227) | ​ | ​ | 46,597 | ​ | $ | (1,865,207) | ​ | $ | 1,438,910
Net income |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 60,832 | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | ​ | 60,832
Stock-based compensation |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 10,263 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | 10,263
Net activity from stock-based compensation awards |  | ​ | 13 | ​ | ​ | ​ | ​ | ​ | 175 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 2 | ​ | ​ | (259) |  | ​ | (84)
Proceeds from stock issued under Colleague Stock Purchase Plan |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 222 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (4) | ​ | ​ | 173 |  | ​ | 395
Repurchases of common stock for treasury | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 792 | ​ | ​ | (77,603) | ​ | ​ | (77,603)
March 31, 2025 | ​ | ​ | 83,899 | ​ | $ | 839 | ​ | $ | 653,635 | ​ | $ | 2,723,362 | ​ | $ | (2,227) | ​ | ​ | 47,387 | ​ | $ | (1,942,896) | ​ | $ | 1,432,713
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
June 30, 2023 | ​ | ​ | 82,232 | ​ | $ | 822 | ​ | $ | 568,761 | ​ | $ | 2,403,750 | ​ | $ | (2,227) | ​ | ​ | 39,922 | ​ | $ | (1,513,770) | ​ | $ | 1,457,336
Net income |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | 87,358 |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | 87,358
Stock-based compensation |  | ​ | ​ |  | ​ | ​ |  | ​ | 19,405 |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | 19,405
Net activity from stock-based compensation awards |  | ​ | 868 |  | ​ | 9 |  | ​ | 15,402 |  | ​ | ​ |  | ​ | ​ |  | ​ | 147 |  | ​ | (6,600) |  | ​ | 8,811
Proceeds from stock issued under Colleague Stock Purchase Plan | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 103 | ​ | ​ | (18) | ​ | ​ | ​ | ​ | ​ | (15) | ​ | ​ | 562 | ​ | ​ | 647
Repurchases of common stock for treasury | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 5,281 | ​ | ​ | (252,594) | ​ | ​ | (252,594)
March 31, 2024 | ​ | ​ | 83,100 | ​ | $ | 831 | ​ | $ | 603,671 | ​ | $ | 2,491,090 | ​ | $ | (2,227) | ​ | ​ | 45,335 | ​ | $ | (1,772,402) | ​ | $ | 1,320,963
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
June 30, 2024 | ​ | ​ | 83,194 | ​ | $ | 832 | ​ | $ | 611,949 | ​ | $ | 2,540,509 | ​ | $ | (2,227) | ​ | ​ | 45,513 | ​ | $ | (1,781,928) | ​ | $ | 1,369,135
Net income |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 182,853 | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ |  | ​ | 182,853
Stock-based compensation |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 31,181 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |  | ​ | 31,181
Net activity from stock-based compensation awards |  | ​ | 705 | ​ | ​ | 7 | ​ | ​ | 10,001 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 162 | ​ | ​ | (12,457) |  | ​ | (2,449)
Proceeds from stock issued under Colleague Stock Purchase Plan |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 504 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (13) | ​ | ​ | 521 |  | ​ | 1,025
Repurchases of common stock for treasury | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 1,725 | ​ | ​ | (149,032) | ​ | ​ | (149,032)
March 31, 2025 | ​ | ​ | 83,899 | ​ | $ | 839 | ​ | $ | 653,635 | ​ | $ | 2,723,362 | ​ | $ | (2,227) | ​ | ​ | 47,387 | ​ | $ | (1,942,896) | ​ | $ | 1,432,713

​

See accompanying Notes to Consolidated Financial Statements.

​

4

Table of Contents

Adtalem Global Education Inc.

Notes to Consolidated Financial Statements

(unaudited)

Table of Contents

​

Note |  | Page
1 | Nature of Operations | 6
2 | Summary of Significant Accounting Policies | 6
3 | Discontinued Operations | 8
4 | Revenue | 8
5 | Restructuring Expense | 10
6 | Other Income, Net | 11
7 | Income Taxes | 11
8 | Earnings per Share | 12
9 | Accounts and Financing Receivables | 12
10 | Property and Equipment, Net | 15
11 | Leases | 15
12 | Goodwill and Intangible Assets | 16
13 | Debt | 18
14 | Share Repurchases | 21
15 | Stock-Based Compensation | 21
16 | Fair Value Measurements | 23
17 | Commitments and Contingencies | 24
18 | Segment Information | 25

​

​

5

Table of Contents

1. Nature of Operations

In this Quarterly Report on Form 10-Q, Adtalem Global Education Inc., together with its subsidiaries, is collectively referred to as “Adtalem,” “we,” “our,” “us,” or similar references. Adtalem reports on a fiscal year period ending on June 30. Therefore, this Quarterly Report for the quarterly period ended March 31, 2025 is for our third quarter of fiscal year 2025.

Adtalem is the leading healthcare educator in the U.S. Our schools consist of Chamberlain University (“Chamberlain”), Walden University (“Walden”), American University of the Caribbean School of Medicine (“AUC”), Ross University School of Medicine (“RUSM”), and Ross University School of Veterinary Medicine (“RUSVM”). AUC, RUSM, and RUSVM are collectively referred to as the “medical and veterinary schools.” “Home Office” includes activities not allocated to a reportable segment. See Note 18 “Segment Information” for information on our reportable segments.

2. Summary of Significant Accounting Policies

Basis of Presentation

Our significant accounting policies are described in Note 2 “Summary of Significant Accounting Policies” of our Annual Report on Form 10-K for the fiscal year ended June 30, 2024 (the “2024 Form 10-K”). We have prepared the accompanying unaudited consolidated financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (which are normal and recurring in nature) considered necessary for a fair presentation have been included. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. We use the same accounting policies in preparing quarterly and annual financial statements. Unless otherwise noted, amounts presented within the Notes to Consolidated Financial Statements refer to our continuing operations. Unless indicated, or the context requires otherwise, references to years refer to Adtalem’s fiscal years. Certain items presented in tables may not sum due to rounding. Prior period amounts have been revised to conform with the current period presentation. These consolidated financial statements and accompanying notes should be read in conjunction with our annual consolidated financial statements and the notes thereto included in our 2024 Form 10-K.

Business integration expense was $18.5 million and $30.6 million in the three and nine months ended March 31, 2024, respectively. We did not incur business integration expense in the three and nine months ended March 31, 2025. In the prior year, we incurred costs associated with integrating Walden into Adtalem. In addition, we initiated transformation initiatives to accelerate growth and organizational agility and certain costs relating to the transformation were included in business integration expense in the Consolidated Statements of Income.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Recent Accounting Standards

In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2024-03: “Income Statement–Reporting Comprehensive Income–Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.” The guidance was issued to improve the disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses in commonly presented expense captions as well as disclosures about selling expenses. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. The amendments should be applied prospectively, however retrospective application is permitted. Early adoption of the amendments is permitted, including adoption in an interim period. The amendments

6

Table of Contents

will expand our footnote disclosures to include a disaggregation of expenses in accordance with the amendments but will not otherwise impact Adtalem’s Consolidated Financial Statements.

In November 2023, the FASB issued ASU No. 2023-07: “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The guidance was issued to improve disclosures about reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses by requiring entities to provide disclosures of significant segment expenses and other segment items. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The amendments should be applied retrospectively. Early adoption of the amendments is permitted, including adoption in an interim period. The amendments will impact our segment disclosures but will not otherwise impact Adtalem’s Consolidated Financial Statements.

In December 2023, the FASB issued ASU No. 2023-09: “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The guidance was issued to enhance the transparency and decision usefulness of income tax disclosures by requiring entities to provide additional information in the rate reconciliation and additional disclosures about income taxes paid. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2024. The amendments should be applied prospectively, however retrospective application is permitted. Early adoption of the amendments is permitted. The amendments will impact our income tax disclosures but will not otherwise impact Adtalem’s Consolidated Financial Statements.

We reviewed all other recently issued accounting pronouncements and concluded that they were either not applicable or not expected to have a significant impact on our Consolidated Financial Statements.

Revision to Previously Issued Financial Statements

During the fourth quarter of fiscal year 2024, Adtalem identified an error in the presentation of capitalized cloud computing implementation costs in its previously issued financial statements. In accordance with Accounting Standards Codification (“ASC”) 350-40 “Intangibles, Goodwill and Other, Internal-Use Software,” capitalized cloud computing implementation costs should be presented in the same line item on the Consolidated Balance Sheets as a prepayment of the fees for the associated hosting arrangement, and the cash flows from capitalized implementation costs should be presented in the same manner as cash flows for the fees associated with the hosting arrangement. Adtalem previously presented capitalized cloud implementation costs in property and equipment, net rather than as prepaid expenses and other current assets and other assets, net on the Consolidated Balance Sheets. Adtalem previously presented the cash flows from capitalized implementation costs as capital expenditures within investing activities rather than within cash flows from operating activities in the Consolidated Statements of Cash Flows. Adtalem assessed the materiality of this error individually and in the aggregate with other previously identified errors to prior periods’ Consolidated Financial Statements in accordance with SEC Staff Accounting Bulletin (“SAB”) No. 99 “Materiality” and SAB 108 “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements” codified in ASC 250 “Accounting Changes and Error Corrections.” Adtalem concluded that the error was not material to prior periods and therefore, amendments of previously filed reports are not required. However, Adtalem determined it was appropriate to revise its previously issued financial statements. In accordance with ASC 250, Adtalem corrected the prior period presented herein by revising the financial statement line item amounts previously disclosed in SEC filings in order to achieve comparability in the Consolidated Financial Statements. The impact of this revision on Adtalem’s previously reported Consolidated Financial Statements are detailed below. We have also revised impacted amounts within the accompanying Notes to Consolidated Financial Statements.

7

Table of Contents

The following table summarizes the effect of the revisions on the affected line items within the Consolidated Statements of Cash Flows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31, 2024
​ | ​ | As Reported | ​ | Adjustment | ​ | As Revised
Operating activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Adjustments to reconcile net income to net cash provided by operating activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation | ​ | $ | 32,106 | ​ | $ | (2,227) | ​ | $ | 29,879
Changes in assets and liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cloud computing implementation assets | ​ | ​ | — | ​ | ​ | (19,262) | ​ | ​ | (19,262)
Accounts payable | ​ | ​ | 10,841 | ​ | ​ | 1,791 | ​ | ​ | 12,632
Net cash provided by operating activities-continuing operations | ​ | ​ | 246,809 | ​ | ​ | (19,698) | ​ | ​ | 227,111
Net cash provided by operating activities | ​ | ​ | 255,205 | ​ | ​ | (19,698) | ​ | ​ | 235,507
Investing activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Capital expenditures | ​ | ​ | (52,014) | ​ | ​ | 19,698 | ​ | ​ | (32,316)
Net cash used in investing activities-continuing operations | ​ | ​ | (51,886) | ​ | ​ | 19,698 | ​ | ​ | (32,188)
Net cash used in investing activities | ​ | ​ | (51,886) | ​ | ​ | 19,698 | ​ | ​ | (32,188)
Non-cash investing and financing activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accrued capital expenditures | ​ | ​ | 11,086 | ​ | ​ | (4,869) | ​ | ​ | 6,217

​

​

3. Discontinued Operations

On December 11, 2018, Adtalem completed the sale of DeVry University to Cogswell Education, LLC (“Cogswell”) for de minimis consideration. As the sale represented a strategic shift that had a major effect on Adtalem’s operations and financial results, DeVry University is presented in Adtalem’s Consolidated Financial Statements as a discontinued operation. The purchase agreement includes an earn-out entitling Adtalem to payments of up to $20.0 million over a ten-year period payable based on DeVry University’s financial results. Adtalem received $7.0 million and $5.5 million during the second quarter of fiscal year 2025 and 2024, respectively, related to the earn-out. To date, we have received a total of $19.5 million related to the earn-out.

The following is a summary of income statement information reported as discontinued operations, which includes expense from ongoing litigation costs and settlements related to divestitures and the earn-outs we received (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Revenue | ​ | $ | — | ​ | $ | — | ​ | $ | — | ​ | $ | —
Operating cost and expense: | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
Student services and administrative expense | ​ |  | (52) | ​ |  | 832 | ​ |  | (6,216) | ​ |  | (329)
Total operating cost and expense | ​ |  | (52) | ​ |  | 832 | ​ |  | (6,216) | ​ |  | (329)
Income (loss) from discontinued operations before income taxes | ​ | ​ | 52 | ​ | ​ | (832) | ​ | ​ | 6,216 | ​ | ​ | 329
(Provision for) benefit from income taxes | ​ |  | (14) | ​ |  | 212 | ​ |  | (1,578) | ​ |  | (84)
Income (loss) from discontinued operations | ​ | $ | 38 | ​ | $ | (620) | ​ | $ | 4,638 | ​ | $ | 245

​

​

4. Revenue

Revenue is recognized when control of the promised goods or services is transferred to our customers (students), in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

8

Table of Contents

The following tables disaggregate revenue by source (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2025
​ | ​ | Chamberlain | ​ | Walden |  | Medical and Veterinary | ​ | Consolidated
Tuition and fees | ​ | $ | 192,592 | ​ | $ | 178,418 |  | $ | 92,597 | ​ | $ | 463,607
Other | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,448 | ​ | ​ | 2,448
Total |  | $ | 192,592 |  | $ | 178,418 |  | $ | 95,045 |  | $ | 466,055

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31, 2025
​ | ​ | Chamberlain | ​ | Walden |  | Medical and Veterinary | ​ | Consolidated
Tuition and fees |  | $ | 541,508 |  | $ | 511,237 |  | $ | 270,605 |  | $ | 1,323,350
Other | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 7,834 | ​ | ​ | 7,834
Total |  | $ | 541,508 |  | $ | 511,237 |  | $ | 278,439 |  | $ | 1,331,184

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2024
​ | ​ | Chamberlain | ​ | Walden |  | Medical and Veterinary | ​ | Consolidated
Tuition and fees | ​ | $ | 170,338 |  | $ | 150,607 |  | $ | 88,271 | ​ | $ | 409,216
Other | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,442 | ​ | ​ | 3,442
Total |  | $ | 170,338 |  | $ | 150,607 |  | $ | 91,713 |  | $ | 412,658

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31, 2024
​ | ​ | Chamberlain | ​ | Walden |  | Medical and Veterinary | ​ | Consolidated
Tuition and fees | ​ | $ | 466,487 |  | $ | 439,023 |  | $ | 258,866 |  | $ | 1,164,376
Other | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 10,369 | ​ | ​ | 10,369
Total |  | $ | 466,487 |  | $ | 439,023 |  | $ | 269,235 |  | $ | 1,174,745

​

In addition, see Note 18 “Segment Information” for a disaggregation of revenue by geographical region.

Performance Obligations and Revenue Recognition

Tuition and fees: The majority of revenue is derived from tuition and fees, which is recognized on a straight-line basis over the academic term as instruction is delivered.

Other: Other revenue consists of housing and other miscellaneous services. Other revenue is recognized over the period in which the applicable performance obligation is satisfied.

Arrangements for payment are agreed to prior to registration of the student’s first academic term. The majority of U.S. students obtain Title IV or other financial aid resulting in institutions receiving a significant amount of the transaction price at the beginning of the academic term. Students not utilizing Title IV or other financial aid funding may pay after the academic term is complete.

Transaction Price

Revenue, or transaction price, is measured as the amount of consideration expected to be received in exchange for transferring goods or services.

Students may receive scholarships, discounts, or refunds, which gives rise to variable consideration. The amounts of scholarships or discounts are generally applied to individual student accounts when such amounts are awarded. Therefore, the transaction price is immediately reduced directly by these scholarships or discounts from the amount of the standard tuition rate charged. Scholarships and discounts that are only applied to future tuition charged are considered a separate performance obligation if they represent a material right in accordance with ASC 606. In those instances, we defer the value of the related performance obligation associated with the future scholarship or discount based on estimates of future

9

Table of Contents

redemption based on our historical experience of student persistence toward completion of study. The contract liability associated with these material rights is presented as deferred revenue within current liabilities and other liabilities within noncurrent liabilities on the Consolidated Balance Sheets based on the amounts expected to be earned in the next 12 months. The contract liability amount associated with these material rights presented as deferred revenue within current liabilities is $35.6 million and $24.1 million as of March 31, 2025 and June 30, 2024, respectively, and the amount presented as deferred revenue within noncurrent liabilities is $23.1 million and $19.6 million as of March 31, 2025 and June 30, 2024, respectively. The noncurrent contract liability associated with these material rights is expected to be earned over approximately the next four fiscal years.

Upon withdrawal, a student may be eligible to receive a refund, or partial refund, the amount of which is dependent on the timing of the withdrawal during the academic term. If a student withdraws prior to completing an academic term, federal and state regulations and accreditation criteria permit Adtalem to retain a set percentage of the total tuition received from such student, which varies with, but generally equals or exceeds, the percentage of the academic term completed by such student. Payment amounts received by Adtalem in excess of such set percentages of tuition are refunded to the student or the appropriate funding source. For contracts with similar characteristics and historical data on refunds, the expected value method is applied in determining the variable consideration related to refunds. Estimates of Adtalem’s expected refunds are determined at the outset of each academic term, based upon actual refunds in previous academic terms. Reserves related to refunds are presented as refund liabilities within accrued liabilities on the Consolidated Balance Sheets. All refunds are netted against revenue during the applicable academic term.

Management reassesses collectability on a student-by-student basis throughout the period revenue is recognized. This reassessment is based upon new information and changes in facts and circumstances relevant to a student’s ability to pay. Management also reassesses collectability when a student withdraws from the institution and has unpaid tuition charges. Such unpaid charges do not meet the threshold of reasonably collectible and are recognized as revenue on a cash basis.

Contract Balances

Students are billed at the beginning of each academic term and payment is due at that time. Adtalem’s performance obligation is to provide educational services in the form of instruction during the academic term and to provide for any scholarships or discounts that are deemed a material right under ASC 606. As instruction is provided or the deferred value of material rights are recognized, deferred revenue is reduced. A significant portion of student payments are from Title IV financial aid and other programs and are generally received during the first month of the respective academic term. For students utilizing Adtalem’s credit extension programs (see Note 9 “Accounts and Financing Receivables”), payments are generally received after the academic term, and the corresponding performance obligation, is complete. When payments are received, accounts and financing receivables are reduced.

Deferred revenue within current liabilities is $247.8 million and $185.3 million as of March 31, 2025 and June 30, 2024, respectively, and deferred revenue within noncurrent liabilities is $23.1 million and $19.6 million as of March 31, 2025 and June 30, 2024, respectively. Revenue of $6.1 million and $179.3 million was recognized during the three and nine months ended March 31, 2025, respectively, that was included in the deferred revenue balance at the beginning of fiscal year 2025. Revenue of $0.9 million and $153.0 million was recognized in the three and nine months ended March 31, 2024, respectively, that was included in the deferred revenue balance at the beginning of fiscal year 2024.

The difference between the opening and closing balances of deferred revenue includes decreases from revenue recognized during the period, increases from charges related to the start of academic terms beginning during the period, increases from payments received related to academic terms commencing after the end of the period, and increases from recognizing additional performance obligations for material rights during the period.

5. Restructuring Expense

During the nine months ended March 31, 2025, Adtalem recorded restructuring expense primarily driven by workforce reductions, costs to exit certain course offerings, and prior real estate consolidations at Adtalem’s home office. We continue to incur restructuring charges or reversals related to exited leased space from previous restructuring actions. During the nine months ended March 31, 2024, Adtalem recorded restructuring expense primarily driven by prior real estate consolidations at Adtalem’s home office. When estimating costs of exiting lease space, estimates are made which

10

Table of Contents

could differ materially from actual results and may result in additional restructuring charges or reversals in future periods. Termination benefit charges represent severance pay and benefits for employees impacted by workforce reductions. Restructuring expense by segment were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2025 | ​ | Nine Months Ended March 31, 2025
​ | ​ | Real Estate and Other | ​ | Termination Benefits | ​ | Total | ​ | Real Estate and Other | ​ | Termination Benefits | ​ | Total
Chamberlain |  | $ | — |  | $ | (23) |  | $ | (23) | ​ | $ | 974 |  | $ | 938 |  | $ | 1,912
Medical and Veterinary |  | ​ | 52 |  | ​ | 69 |  | ​ | 121 | ​ | ​ | 167 |  | ​ | 69 |  | ​ | 236
Home Office |  | ​ | 172 |  | ​ | 240 |  | ​ | 412 | ​ | ​ | 538 |  | ​ | 240 |  | ​ | 778
Total | ​ | $ | 224 | ​ | $ | 286 | ​ | $ | 510 | ​ | $ | 1,679 | ​ | $ | 1,247 | ​ | $ | 2,926

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2024 | ​ | Nine Months Ended March 31, 2024
​ | ​ | Real Estate and Other | ​ | Termination Benefits | ​ | Total | ​ | Real Estate and Other | ​ | Termination Benefits | ​ | Total
Walden |  | $ | — |  | $ | — |  | $ | — | ​ | $ | (776) |  | $ | — |  | $ | (776)
Medical and Veterinary |  | ​ | 194 |  | ​ | — |  | ​ | 194 | ​ | ​ | 339 |  | ​ | 40 |  | ​ | 379
Home Office |  | ​ | 279 |  | ​ | — |  | ​ | 279 | ​ | ​ | 1,614 |  | ​ | — |  | ​ | 1,614
Total | ​ | $ | 473 | ​ | $ | — | ​ | $ | 473 | ​ | $ | 1,177 | ​ | $ | 40 | ​ | $ | 1,217

​

The following table summarizes the separation and restructuring plan activity for fiscal years 2024 and 2025, for which cash payments are required (in thousands):

​

​ | ​ | ​ | ​
Liability balance as of June 30, 2023 | ​ | $ | 741
Increase in liability (separation and other charges) | ​ |  | 40
Reduction in liability (payments and adjustments) | ​ |  | (781)
Liability balance as of June 30, 2024 | ​ |  | —
Increase in liability (separation and other charges) | ​ |  | 1,247
Reduction in liability (payments and adjustments) | ​ |  | (1,059)
Liability balance as of March 31, 2025 | ​ | $ | 188

​

These liability balances are recorded as accrued liabilities on the Consolidated Balance Sheets.

6. Other Income, Net

Other income, net consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Interest and dividend income | ​ | $ | 2,072 | ​ | $ | 2,165 | ​ | $ | 6,511 | ​ | $ | 7,367
Investment (loss) gain | ​ | ​ | (174) | ​ | ​ | 706 | ​ | ​ | 268 | ​ | ​ | 1,281
Other income, net | ​ | $ | 1,898 | ​ | $ | 2,871 | ​ | $ | 6,779 | ​ | $ | 8,648

​

Investment (loss) gain includes trading gains and losses related to the rabbi trust used to fund nonqualified deferred compensation plan obligations.

7. Income Taxes

Our effective tax rate from continuing operations was 23.4% and 22.5% in the three and nine months ended March 31, 2025, respectively, and 22.1% and 19.5% in the three and nine months ended March 31, 2024, respectively. The effective tax rate for the three and nine months ended March 31, 2025 increased compared to the prior year periods primarily due to an increase in the percentage of earnings from operations in higher taxed jurisdictions and a limitation of tax benefits on certain executive compensation. The income tax provisions reflect the U.S. federal tax rate of 21% adjusted for taxes related to global intangible low-taxed income (“GILTI”), limitation of tax benefits on certain executive compensation, the

11

Table of Contents

rate of tax applied by state and local jurisdictions, the rate of tax applied to earnings outside the U.S., tax incentives, tax credits related to research and development expenditures, changes in valuation allowance, changes in uncertain tax positions, and tax benefits on stock-based compensation.

RUSM and RUSVM each have agreements with their respective domestic governments that exempt them from local income taxation. RUSM has an exemption in Barbados until 2039 and RUSVM has an exemption in St. Kitts until 2038.

8. Earnings per Share

The following table sets forth the computations of basic and diluted earnings per share and antidilutive shares (in thousands, except per share data):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Numerator: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income (loss): | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​
Continuing operations | ​ | $ | 60,794 | ​ | $ | 37,441 | ​ | $ | 178,215 | ​ | $ | 87,113
Discontinued operations | ​ | ​ | 38 | ​ | ​ | (620) | ​ | ​ | 4,638 | ​ | ​ | 245
Net income | ​ | $ | 60,832 | ​ | $ | 36,821 | ​ | $ | 182,853 | ​ | $ | 87,358
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Denominator: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average basic shares outstanding |  | ​ | 37,140 | ​ |  | 38,713 |  | ​ | 37,434 |  | ​ | 40,000
Effect of dilutive stock awards |  | ​ | 1,093 | ​ |  | 923 |  | ​ | 1,149 |  | ​ | 874
Weighted-average diluted shares outstanding |  | ​ | 38,233 | ​ |  | 39,636 |  | ​ | 38,583 |  | ​ | 40,874
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Earnings (loss) per share: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Continuing operations | ​ | $ | 1.64 | ​ | $ | 0.97 | ​ | $ | 4.76 | ​ | $ | 2.18
Discontinued operations | ​ | $ | 0.00 | ​ | $ | (0.02) | ​ | $ | 0.12 | ​ | $ | 0.01
Total basic earnings per share | ​ | $ | 1.64 | ​ | $ | 0.95 | ​ | $ | 4.88 | ​ | $ | 2.18
Diluted: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Continuing operations | ​ | $ | 1.59 | ​ | $ | 0.94 | ​ | $ | 4.62 | ​ | $ | 2.13
Discontinued operations | ​ | $ | 0.00 | ​ | $ | (0.02) | ​ | $ | 0.12 | ​ | $ | 0.01
Total diluted earnings per share | ​ | $ | 1.59 | ​ | $ | 0.93 | ​ | $ | 4.74 | ​ | $ | 2.14
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Weighted-average antidilutive shares | ​ | ​ | 1 | ​ | ​ | 2 | ​ | ​ | 30 | ​ | ​ | 141

​

​

9. Accounts and Financing Receivables

Our accounts receivables relate to student balances occurring in the normal course of business. Accounts receivables have a term of less than one year and are included in accounts and financing receivables, net on our Consolidated Balance Sheets. Our financing receivables relate to credit extension programs, which provide students with payment terms in excess of one year and are included in accounts and financing receivables, net and other assets, net on our Consolidated Balance Sheets.

12

Table of Contents

The classification of our accounts and financing receivable balances was as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, 2025
​ | ​ | ​ | Gross | ​ | ​ | Allowance | ​ | ​ | Net
Accounts receivables, current | ​ | $ | 204,541 | ​ | $ | (44,183) | ​ | $ | 160,358
Financing receivables, current | ​ | ​ | 5,361 | ​ | ​ | (2,747) | ​ | ​ | 2,614
Accounts and financing receivables, current | ​ | $ | 209,902 | ​ | $ | (46,930) | ​ | $ | 162,972
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Financing receivables, current | ​ | $ | 5,361 | ​ | $ | (2,747) | ​ | $ | 2,614
Financing receivables, noncurrent | ​ | ​ | 33,421 | ​ | ​ | (9,669) | ​ | ​ | 23,752
Total financing receivables | ​ | $ | 38,782 | ​ | $ | (12,416) | ​ | $ | 26,366

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | June 30, 2024
​ | ​ | ​ | Gross | ​ | ​ | Allowance | ​ | ​ | Net
Accounts receivables, current | ​ | $ | 159,406 | ​ | $ | (35,336) | ​ | $ | 124,070
Financing receivables, current | ​ | ​ | 5,239 | ​ | ​ | (2,476) | ​ | ​ | 2,763
Accounts and financing receivables, current | ​ | $ | 164,645 | ​ | $ | (37,812) | ​ | $ | 126,833
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Financing receivables, current | ​ | $ | 5,239 | ​ | $ | (2,476) | ​ | $ | 2,763
Financing receivables, noncurrent | ​ | ​ | 36,214 | ​ | ​ | (10,082) | ​ | ​ | 26,132
Total financing receivables | ​ | $ | 41,453 | ​ | $ | (12,558) | ​ | $ | 28,895

​

Our financing receivables relate to credit extension programs available to students at Chamberlain, AUC, RUSM, and RUSVM. These credit extension programs are designed to assist students who are unable to completely cover educational costs consisting of tuition, fees, and books, and are available only after all other student financial assistance has been applied toward those purposes. In addition, AUC, RUSM, and RUSVM allow students to finance their living expenses. Repayment plans for financing agreements are developed to address the financial circumstances of the particular student. Interest charges at rates from 3.0% to 12.0% per annum accrue each month on the unpaid balance once a student withdraws or graduates from a program. Most students are required to begin repaying their loans while they are still in school with a minimum payment level. Payments may increase upon completing or departing school.

Credit Quality

The primary credit quality indicator for our financing receivables is delinquency. Balances are considered delinquent when contractual payments on the loan become past due. We generally write-off financing receivable balances when they are at least 181 days past due. Payments are applied first to outstanding interest and then to the unpaid principal balance.

The credit quality analysis of financing receivables as of March 31, 2025 was as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Amortized Cost Basis by Origination Year | ​ | ​ | ​
​ | ​ | Prior | ​ | 2021 | ​ | 2022 | ​ | 2023 | ​ | 2024 | ​ | 2025 | ​ | Total
1-30 days past due |  | $ | 185 | ​ | $ | 121 |  | $ | 190 |  | $ | 47 |  | $ | 734 |  | $ | 152 |  | $ | 1,429
31-60 days past due | ​ | ​ | 115 | ​ | ​ | 169 | ​ | ​ | 80 | ​ | ​ | 348 | ​ | ​ | 88 | ​ | ​ | 383 | ​ | ​ | 1,183
61-90 days past due | ​ | ​ | 62 | ​ | ​ | — | ​ | ​ | 9 | ​ | ​ | 20 | ​ | ​ | 20 | ​ | ​ | — | ​ | ​ | 111
91-120 days past due | ​ | ​ | 87 | ​ | ​ | 24 | ​ | ​ | — | ​ | ​ | 74 | ​ | ​ | 30 | ​ | ​ | 53 | ​ | ​ | 268
121-150 days past due | ​ | ​ | 14 | ​ | ​ | 5 | ​ | ​ | 38 | ​ | ​ | — | ​ | ​ | 88 | ​ | ​ | 30 | ​ | ​ | 175
Greater than 150 days past due | ​ | ​ | 2,669 | ​ | ​ | 1,336 | ​ | ​ | 1,127 | ​ | ​ | 1,894 | ​ | ​ | 2,782 | ​ | ​ | 216 | ​ | ​ | 10,024
Total past due | ​ | ​ | 3,132 | ​ | ​ | 1,655 | ​ | ​ | 1,444 | ​ | ​ | 2,383 | ​ | ​ | 3,742 | ​ | ​ | 834 | ​ | ​ | 13,190
Current | ​ | ​ | 6,149 | ​ | ​ | 2,890 | ​ | ​ | 1,632 | ​ | ​ | 3,261 | ​ | ​ | 6,036 | ​ | ​ | 5,624 | ​ | ​ | 25,592
Financing receivables, gross | ​ | $ | 9,281 | ​ | $ | 4,545 | ​ | $ | 3,076 | ​ | $ | 5,644 | ​ | $ | 9,778 | ​ | $ | 6,458 | ​ | $ | 38,782
Gross write-offs | ​ | $ | 888 | ​ | $ | 620 | ​ | $ | 441 | ​ | $ | 815 | ​ | $ | 571 | ​ | $ | — | ​ | $ | 3,335

​

13

Table of Contents

The credit quality analysis of financing receivables as of June 30, 2024 was as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Amortized Cost Basis by Origination Year | ​ | ​ | ​
​ | ​ | Prior | ​ | 2020 | ​ | 2021 | ​ | 2022 | ​ | 2023 | ​ | 2024 | ​ | Total
1-30 days past due |  | $ | 552 | ​ | $ | — |  | $ | 214 |  | $ | 111 |  | $ | 1,188 |  | $ | 1,146 |  | $ | 3,211
31-60 days past due | ​ | ​ | 213 | ​ | ​ | 90 | ​ | ​ | 65 | ​ | ​ | 37 | ​ | ​ | 567 | ​ | ​ | 1,488 | ​ | ​ | 2,460
61-90 days past due | ​ | ​ | 174 | ​ | ​ | — | ​ | ​ | 5 | ​ | ​ | 110 | ​ | ​ | 370 | ​ | ​ | 257 | ​ | ​ | 916
91-120 days past due | ​ | ​ | — | ​ | ​ | 11 | ​ | ​ | 434 | ​ | ​ | 20 | ​ | ​ | 206 | ​ | ​ | 791 | ​ | ​ | 1,462
121-150 days past due | ​ | ​ | 51 | ​ | ​ | 88 | ​ | ​ | 63 | ​ | ​ | 314 | ​ | ​ | 268 | ​ | ​ | 91 | ​ | ​ | 875
Greater than 150 days past due | ​ | ​ | 2,556 | ​ | ​ | 466 | ​ | ​ | 1,366 | ​ | ​ | 1,300 | ​ | ​ | 1,920 | ​ | ​ | 987 | ​ | ​ | 8,595
Total past due | ​ | ​ | 3,546 | ​ | ​ | 655 | ​ | ​ | 2,147 | ​ | ​ | 1,892 | ​ | ​ | 4,519 | ​ | ​ | 4,760 | ​ | ​ | 17,519
Current | ​ | ​ | 6,014 | ​ | ​ | 748 | ​ | ​ | 3,944 | ​ | ​ | 1,897 | ​ | ​ | 4,549 | ​ | ​ | 6,782 | ​ | ​ | 23,934
Financing receivables, gross | ​ | $ | 9,560 | ​ | $ | 1,403 | ​ | $ | 6,091 | ​ | $ | 3,789 | ​ | $ | 9,068 | ​ | $ | 11,542 | ​ | $ | 41,453
Gross write-offs | ​ | $ | 1,145 | ​ | $ | 279 | ​ | $ | 509 | ​ | $ | 597 | ​ | $ | 729 | ​ | $ | 2 | ​ | $ | 3,261

​

Allowance for Credit Losses

The allowance for credit losses represents an estimate of the lifetime expected credit losses inherent in our accounts and financing receivable balances as of each balance sheet date. In evaluating the collectability of our accounts and financing receivable balances, we utilize historical events, current conditions, and reasonable and supportable forecasts about the future.

For our accounts receivables, we use historical loss rates based on an aging schedule and a student’s status to determine the allowance for credit losses. As these accounts receivables are short-term in nature, management believes a student’s status provides the best credit loss estimate, while also factoring in delinquency. Students still attending classes, recently graduated, or current on payments are more likely to pay than those who are inactive due to being on a leave of absence, withdrawing from school, or not current on payments.

For our financing receivables, we use historical loss rates based on an aging schedule. As these financing receivables are based on long-term financing agreements offered by Adtalem, management believes that delinquency provides the best credit loss estimate. As the financing receivable balances become further past due, it is less likely we will receive payment, causing our estimate of credit losses to increase.

The following tables provide a roll-forward of the allowance for credit losses (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2025 |  | Nine Months Ended March 31, 2025
​ | ​ | Accounts | ​ | Financing | ​ | Total |  | Accounts | ​ | Financing | ​ | Total
Beginning balance |  | $ | 36,752 | ​ | $ | 13,059 |  | $ | 49,811 | ​ | $ | 35,336 | ​ | $ | 12,558 |  | $ | 47,894
Write-offs | ​ | ​ | (13,441) | ​ | ​ | (962) | ​ | ​ | (14,403) | ​ | ​ | (43,311) | ​ | ​ | (3,335) | ​ | ​ | (46,646)
Recoveries | ​ | ​ | 2,941 | ​ | ​ | 115 | ​ | ​ | 3,056 | ​ | ​ | 7,725 | ​ | ​ | 772 | ​ | ​ | 8,497
Provision for credit losses | ​ | ​ | 17,931 | ​ | ​ | 204 | ​ | ​ | 18,135 | ​ | ​ | 44,433 | ​ | ​ | 2,421 | ​ | ​ | 46,854
Ending balance | ​ | $ | 44,183 | ​ | $ | 12,416 | ​ | $ | 56,599 | ​ | $ | 44,183 | ​ | $ | 12,416 | ​ | $ | 56,599

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2024 | ​ | Nine Months Ended March 31, 2024
​ | ​ | Accounts | ​ | Financing | ​ | Total | ​ | Accounts | ​ | Financing | ​ | Total
Beginning balance |  | $ | 35,020 | ​ | $ | 13,326 |  | $ | 48,346 | ​ | $ | 29,190 | ​ | $ | 11,468 |  | $ | 40,658
Write-offs | ​ | ​ | (13,374) | ​ | ​ | (1,880) | ​ | ​ | (15,254) | ​ | ​ | (32,925) | ​ | ​ | (3,037) | ​ | ​ | (35,962)
Recoveries | ​ | ​ | 2,973 | ​ | ​ | 649 | ​ | ​ | 3,622 | ​ | ​ | 7,901 | ​ | ​ | 1,093 | ​ | ​ | 8,994
Provision for credit losses | ​ | ​ | 13,254 | ​ | ​ | (537) | ​ | ​ | 12,717 | ​ | ​ | 33,707 | ​ | ​ | 2,034 | ​ | ​ | 35,741
Ending balance | ​ | $ | 37,873 | ​ | $ | 11,558 | ​ | $ | 49,431 | ​ | $ | 37,873 | ​ | $ | 11,558 | ​ | $ | 49,431

​

​

​

14

Table of Contents

10. Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | March 31, | ​ | June 30,
​ | ​ | Useful Life | ​ | 2025 | ​ | 2024
Land |  | - |  | $ | 31,776 | ​ | $ | 31,776
Buildings and improvements | ​ | 10 - 31 years | ​ | ​ | 202,150 | ​ | ​ | 200,274
Leasehold improvements | ​ | Shorter of asset useful life or lease term | ​ | ​ | 116,375 | ​ | ​ | 114,019
Furniture and equipment | ​ | 3 - 8 years | ​ | ​ | 100,959 | ​ | ​ | 103,961
Software | ​ | 3 - 5 years | ​ | ​ | 111,076 | ​ | ​ | 113,219
Construction in progress | ​ | - | ​ | ​ | 20,625 | ​ | ​ | 11,554
Property and equipment, gross | ​ | ​ | ​ | ​ | 582,961 | ​ | ​ | 574,803
Accumulated depreciation | ​ | ​ | ​ |  | (332,197) | ​ |  | (326,279)
Property and equipment, net | ​ | ​ | ​ | $ | 250,764 | ​ | $ | 248,524

​

During the second quarter of fiscal year 2024, management committed to a plan to sell a building owned by Adtalem located in Naperville, Illinois, and the building met criteria to be classified as assets held for sale. As a result, the building’s carrying value of $8.4 million was adjusted to its estimated fair value less cost to sell of $7.8 million, and the resulting $0.6 million charge was recognized within student services and administrative expense in the Consolidated Statements of Income for the nine months ended March 31, 2024. In addition, the building is presented as assets held for sale on the Consolidated Balance Sheets as of March 31, 2025 and June 30, 2024.

​

11. Leases

We determine if a contract contains a lease at inception. We have entered into operating leases for academic sites, housing facilities, and office space which expire at various dates through August 2040, most of which include options to terminate for a fee or extend the leases for an additional five-year period. The lease term includes the noncancelable period of the lease, as well as any periods for which we are reasonably certain to exercise extension options. We elected to account for lease and non-lease components (e.g., common-area maintenance costs) as a single lease component for all operating leases. Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. We have not entered into any financing leases.

Operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets represent our right to use an underlying asset during the lease term. Operating lease assets and liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. Operating lease assets are adjusted for any prepaid or accrued lease payments, lease incentives, initial direct costs, and impairments. Our incremental borrowing rate is utilized in determining the present value of the lease payments based upon the information available at the commencement date. Our incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease. Operating lease expense is recognized on a straight-line basis over the lease term.

The components of lease cost were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, |  | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Operating lease cost | ​ | $ | 11,712 | ​ | $ | 10,944 | ​ | $ | 33,822 | ​ | $ | 34,014
Sublease income | ​ |  | (1,260) | ​ |  | (1,928) | ​ |  | (4,054) | ​ |  | (7,310)
Total lease cost | ​ | $ | 10,452 | ​ | $ | 9,016 | ​ | $ | 29,768 | ​ | $ | 26,704

​

15

Table of Contents

Maturities of lease liabilities as of March 31, 2025 were as follows (in thousands):

​

​ | ​ | ​ | ​
​ | ​ | Operating
Fiscal Year | ​ | Leases
2025 (remaining) | ​ | $ | 12,407
2026 | ​ | ​ | 49,916
2027 | ​ | ​ | 49,517
2028 | ​ | ​ | 44,943
2029 | ​ | ​ | 36,608
Thereafter | ​ | ​ | 164,552
Total lease payments | ​ |  | 357,943
Less: lease incentives not yet received | ​ | ​ | (25,216)
Less: imputed interest | ​ | ​ | (104,385)
Present value of lease liabilities | ​ | $ | 228,342

​

Lease term and discount rate were as follows:

​

​ | ​ | ​ | ​
​ | ​ | March 31,
​ | ​ | 2025
Weighted-average remaining operating lease term (years) | ​ | ​ | 7.7
Weighted-average operating lease discount rate | ​ | ​ | 7.6%

​

Supplemental disclosures of cash flow information related to leases were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Cash paid for amounts in the measurement of operating lease liabilities (net of sublease receipts) | ​ | $ | 9,388 | ​ | $ | 9,596 | ​ | $ | 25,673 | ​ | $ | 31,210
Operating lease assets obtained in exchange for operating lease liabilities | ​ | $ | 20,903 | ​ | $ | — | ​ | $ | 47,040 | ​ | $ | 19,526

​

Adtalem maintains agreements to sublease either a portion or the full leased space at two of its operating lease locations. Adtalem’s sublease agreements expire at various dates through December 2025. We record sublease income as an offset against our lease expense recorded on the head lease. For leases which Adtalem vacated or partially vacated space, we recorded estimated restructuring charges in prior periods. Actual results may differ from these estimates, which could result in additional restructuring charges or reversals in future periods. Future minimum sublease rental income under these agreements as of March 31, 2025 was as follows (in thousands):

​

​ | ​ | ​ | ​
Fiscal Year | ​ | Amount
2025 (remaining) | ​ | $ | 1,252
2026 | ​ | ​ | 2,038
Total sublease rental income | ​ | $ | 3,290

​

​

12. Goodwill and Intangible Assets

Goodwill balances by reportable segment were as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | June 30,
​ | ​ | 2025 | ​ | 2024
Chamberlain | ​ | $ | 4,716 | ​ | $ | 4,716
Walden | ​ | ​ | 651,052 | ​ | ​ | 651,052
Medical and Veterinary | ​ | ​ | 305,494 | ​ | ​ | 305,494
Total | ​ | $ | 961,262 | ​ | $ | 961,262

​

16

Table of Contents

Amortizable intangible assets consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, 2025 | ​ | June 30, 2024 | ​ | ​
​ | ​ | Gross Carrying | ​ | Accumulated | ​ | Gross Carrying | ​ | Accumulated | ​ | Weighted-Average
​ | ​ | Amount | ​ | Amortization | ​ | Amount | ​ | Amortization | ​ | Amortization Period
Curriculum | ​ | $ | 56,091 | ​ | $ | (40,672) |  | $ | 56,091 | ​ | $ | (32,257) |  | 5 Years
Total | ​ | $ | 56,091 | ​ | $ | (40,672) |  | $ | 56,091 | ​ | $ | (32,257) |  | ​

​

Indefinite-lived intangible assets consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | June 30,
​ | ​ | 2025 | ​ | 2024
Title IV eligibility and accreditations | ​ | $ | 611,100 | ​ | $ | 611,100
Trade name | ​ |  | 141,760 | ​ |  | 141,760
Total | ​ | $ | 752,860 | ​ | $ | 752,860

​

Amortization expense on finite-lived intangible assets was $2.8 million and $8.4 million in the three and nine months ended March 31, 2025, respectively, and $8.3 million and $28.3 million in the three and nine months ended March 31, 2024, respectively. Future amortization expense on finite-lived intangible assets, by reporting unit, is expected to be as follows (in thousands):

​

​ | ​ | ​ | ​
Fiscal Year | ​ | Walden
2025 (remaining) | ​ | $ | 2,805
2026 | ​ |  | 11,220
2027 | ​ |  | 1,394
Total | ​ | $ | 15,419

​

Curriculum is amortized on a straight-line basis. Student relationships was fully amortized as of June 30, 2024.

Indefinite-lived intangible assets related to trade names and Title IV eligibility and accreditations are not amortized, as there are no legal, regulatory, contractual, economic, or other factors that limit the useful life of these intangible assets to the reporting entity.

Goodwill and indefinite-lived intangible assets are not amortized, but are reviewed for impairment annually and when an event occurs or circumstances change such that it is more likely than not that an impairment may exist. Our annual testing date is May 31.

Adtalem has five reporting units, which are Chamberlain, Walden, AUC, RUSM, and RUSVM. These reporting units constitute components for which discrete financial information is available and regularly reviewed by segment management. We have the option to assess goodwill for impairment by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If it is determined that the reporting unit fair value is more likely than not less than its carrying value, or if we do not elect the option to perform an initial qualitative assessment, we perform a quantitative assessment of the reporting unit’s fair value. If the carrying value of a reporting unit containing the goodwill exceeds the fair value of that reporting unit, an impairment loss is recognized equal to the difference between the carrying value of the reporting unit and its fair value, not to exceed the carrying value of goodwill. We also have the option to perform a qualitative assessment to test indefinite-lived intangible assets for impairment by determining whether it is more likely than not that the indefinite-lived intangible assets are impaired. If it is determined that the indefinite-lived intangible asset is more likely than not impaired, or if we do not elect the option to perform an initial qualitative assessment, we perform a quantitative assessment of the indefinite-lived intangible assets. If the carrying value of the indefinite-lived intangible assets exceeds its fair value, an impairment loss is recognized to the extent the carrying value exceeds fair value.

During the third quarter of fiscal year 2025, Adtalem performed an assessment to determine whether there were indicators of a triggering event which could indicate the carrying value of the reporting units may not be supported by the fair value. No indicators of a triggering event for potential impairment were noted in the third quarter of fiscal year 2025.

17

Table of Contents

If economic conditions deteriorate, or operating performance of our reporting units do not meet expectations such that we revise our long-term forecasts, we may recognize impairments of goodwill and other intangible assets in future periods.

13. Debt

Long-term debt consisted of the following senior secured credit facilities (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | March 31, | ​ | June 30,
​ | ​ | 2025 | ​ | 2024
Senior Secured Notes due 2028 | ​ | $ | 404,950 | ​ | $ | 404,950
Term Loan B | ​ |  | 153,333 | ​ |  | 253,333
Total principal | ​ |  | 558,283 | ​ |  | 658,283
Unamortized debt discount and issuance costs | ​ |  | (6,097) | ​ |  | (9,571)
Long-term debt | ​ | $ | 552,186 | ​ | $ | 648,712

​

Scheduled future maturities of long-term debt were as follows (in thousands):

​

​ | ​ | ​ | ​
​ | ​ | Maturity
Fiscal Year | ​ | Payments
2025 (remaining) | ​ | $ | —
2026 | ​ |  | —
2027 | ​ |  | —
2028 | ​ |  | 404,950
2029 | ​ | ​ | 153,333
Total | ​ | $ | 558,283

​

Senior Secured Notes due 2028

On March 1, 2021, Adtalem issued $800.0 million aggregate principal amount of 5.50% Senior Secured Notes due 2028 (the “Notes”), which mature on March 1, 2028, pursuant to an indenture, dated as of March 1, 2021 (the “Indenture”), by and between Adtalem and U.S. Bank National Association, as trustee and notes collateral agent. The Notes were sold within the U.S. only to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the U.S. to non-U.S. persons in reliance on Regulation S under the Securities Act.

The Notes were issued at 100.0% of their par value. The Notes bear interest at a rate of 5.50% per year, payable semi-annually in arrears on March 1 and September 1 of each year, commencing on September 1, 2021, to holders of record on the preceding February 15 and August 15, as the case may be. The Notes are guaranteed by certain of Adtalem’s subsidiaries that are borrowers or guarantors under its senior secured credit facilities and certain of its other senior indebtedness, subject to certain exceptions. The Notes are secured, subject to permitted liens and certain other exceptions, by first priority liens on the same collateral that secures the obligations under Adtalem’s senior secured credit facilities.

We may redeem the Notes, in whole or in part, at any time on or after March 1, 2024 at redemption prices equal to 102.75%, 101.375%, and 100% of the principal amount of the Notes redeemed if the redemption occurs during the twelve-month periods beginning on March 1 of the years 2024, 2025, and 2026 and thereafter, respectively, in each case plus accrued and unpaid interest, if any, thereon to, but not including, the applicable redemption date.

On April 11, 2022, we repaid $373.3 million of Notes at a price equal to 100% of the principal amount of the Notes. During June 2022, we repurchased on the open market an additional $20.8 million of Notes at a price equal to approximately 90% of the principal amount of the Notes. This debt was subsequently retired. During the first quarter of fiscal year 2023, we repurchased on the open market an additional $0.9 million of Notes at a price equal to approximately 92% of the principal amount of the Notes. This debt was subsequently retired. The principal balance of the Notes is $405.0 million as of March 31, 2025.

Accrued interest on the Notes of $1.9 million and $7.4 million is recorded within accrued liabilities on the Consolidated Balance Sheets as of March 31, 2025 and June 30, 2024, respectively.

18

Table of Contents

Credit Agreement

On August 12, 2021, in connection with the Walden acquisition, Adtalem entered into its new credit agreement (the “Credit Agreement”) that provides for (1) a $850.0 million senior secured term loan (“Term Loan B”) with a maturity date of August 12, 2028 and (2) a $400.0 million senior secured revolving loan facility (“Revolver”) with a maturity date of August 12, 2026. We refer to the Term Loan B and Revolver collectively as the “Credit Facility.” The Revolver has availability for letters of credit and currencies other than U.S. dollars of up to $400.0 million.

On June 27, 2023, Adtalem entered into Amendment No. 1 to Credit Agreement, identifying the Secured Overnight Financing Rate (“SOFR”) as the benchmark rate to replace LIBOR for eurocurrency rate loans within the Credit Agreement effective the first quarter of fiscal year 2024.

Term Loan B

Prior to January 26, 2024, borrowings under the Term Loan B bore interest at a rate per annum equal to, at our option, SOFR plus an applicable margin ranging from 4.00% to 4.50%, subject to a SOFR floor of 0.75%, or an alternate base rate (“ABR”) plus an applicable margin ranging from 3.00% to 3.50% depending on Adtalem’s net first lien leverage ratio for such period.

On January 26, 2024, we entered into Amendment No. 2 to Credit Agreement, which resulted in a 0.50% reduction in our Term Loan B interest rate margin. From January 26, 2024 through August 21, 2024, borrowings under the Term Loan B bore interest at a rate per annum equal to, at our option, SOFR plus an applicable margin ranging from 3.50% to 4.00%, subject to a SOFR floor of 0.75%, or an ABR plus an applicable margin ranging from 2.50% to 3.00% depending on Adtalem’s net first lien leverage ratio for such period.

On August 21, 2024, we entered into Amendment No. 3 to Credit Agreement, which resulted in a further 0.75% reduction in our Term Loan B interest rate margin and removed the leverage-based pricing grid. After August 21, 2024, borrowings under the Term Loan B bear interest at a rate per annum equal to, at our option, SOFR plus 2.75%, subject to a SOFR floor of 0.75%, or an ABR plus 1.75%.

As of March 31, 2025, the interest rate for borrowings under the Term Loan B facility was 7.07%, which approximated the effective interest rate. The Term Loan B originally required quarterly installment payments of $2.125 million beginning on March 31, 2022. On March 11, 2022, we made a prepayment of $396.7 million on the Term Loan B. With that prepayment, we are no longer required to make quarterly installment payments. We made additional Term Loan B prepayments of $100.0 million, $50.0 million, $50.0 million, and $100.0 million on September 22, 2022, November 22, 2022, January 26, 2024, and January 17, 2025, respectively. The principal balance of the Term Loan B is $153.3 million as of March 31, 2025.

Revolver

Borrowings under the Revolver bear interest at a rate per annum equal to SOFR, subject to a SOFR floor of 0.75%, plus an applicable margin ranging from 3.75% to 4.25% or an ABR plus an applicable margin ranging from 2.75% to 3.25% depending on Adtalem’s net first lien leverage ratio for such period. There were no borrowings under the Revolver during the nine months ended March 31, 2025 and 2024.

The Credit Agreement requires payment of a commitment fee equal to 0.25% as of March 31, 2025, of the unused portion of the Revolver. The commitment fee expense is recorded within interest expense in the Consolidated Statements of Income. The amount unused under the Revolver was $400.0 million as of March 31, 2025.

Debt Discount and Issuance Costs

The Term Loan B was issued at a price of 99% of its principal amount, resulting in an original issue discount of 1%. The debt discount and issuance costs related to the Notes and Term Loan B are presented as a direct deduction from the face amount of the debt, while the debt issuance costs related to the Revolver are classified as other assets, net on the Consolidated Balance Sheets. The debt discount and issuance costs are amortized as interest expense over seven years for the Notes and Term Loan B and over five years for the Revolver. Based on the $50.0 million and $100.0 million Term

19

Table of Contents

Loan B prepayments on January 26, 2024 and January 17, 2025, we expensed $1.1 million and $1.7 million in interest expense in the Consolidated Statements of Income in the three and nine months ended March 31, 2024 and March 31, 2025, respectively, which was the proportionate amount of the remaining unamortized debt discount and issuance costs related to the Term Loan B as of the prepayment dates. The following table summarizes the unamortized debt discount and issuance costs activity for the nine months ended March 31, 2025 (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Notes | ​ | Term Loan B | ​ | Revolver | ​ | Total
Unamortized debt discount and issuance costs as of June 30, 2024 | ​ | $ | 4,446 | ​ | $ | 5,125 | ​ | $ | 4,327 | ​ | $ | 13,898
Amortization of debt discount and issuance costs | ​ |  | (891) | ​ |  | (845) | ​ |  | (1,521) | ​ |  | (3,257)
Debt discount and issuance costs write-off | ​ | ​ | — | ​ | ​ | (1,738) | ​ | ​ | — | ​ | ​ | (1,738)
Unamortized debt discount and issuance costs as of March 31, 2025 | ​ | $ | 3,555 | ​ | $ | 2,542 | ​ | $ | 2,806 | ​ | $ | 8,903

​

Off-Balance Sheet Arrangements

On December 6, 2024, the U.S. Department of Education (“ED”) notified Adtalem that the $69.4 million surety-backed letter of credit in favor of ED on behalf of Walden, which allows Walden to participate in Title IV programs would be permitted to expire on December 31, 2024. A letter of credit in the amount of $157.9 million, representing 10% of the consolidated Title IV funds Adtalem’s institutions received during fiscal year 2022, was delivered to ED on November 1, 2023 with an expiration date of December 31, 2024. On December 3, 2024, ED requested Adtalem amend the letter of credit to $179.0 million, representing 10% of the consolidated Title IV funds Adtalem’s institutions received during fiscal year 2024 with an expiration date of January 31, 2026. As requested, Adtalem delivered this amended letter of credit to ED on December 13, 2024. Adtalem satisfied this request by securing a $99.0 million letter of credit under its Revolver and an $80.0 million surety-backed letter of credit. In February 2025, Adtalem replaced the $99.0 million letter of credit under its Revolver with a $99.0 million surety-backed letter of credit. As of March 31, 2025, Adtalem had $179.0 million of letters of credit outstanding in favor of ED.

Many states require private-sector postsecondary education institutions to post surety bonds for licensure. In the U.S., Adtalem has posted $66.5 million of surety bonds as of March 31, 2025 with regulatory authorities on behalf of Chamberlain, Walden, AUC, RUSM, and RUSVM.

Interest Expense

Interest expense consisted of the following (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Notes interest expense | ​ | $ | 5,568 | ​ | $ | 5,568 | ​ | $ | 16,704 | ​ | $ | 16,704
Term Loan B interest expense | ​ | ​ | 3,031 | ​ | ​ | 6,097 | ​ | ​ | 13,333 | ​ | ​ | 20,673
Term Loan B debt discount and issuance costs write-off | ​ | ​ | 1,738 | ​ | ​ | 1,113 | ​ | ​ | 1,738 | ​ | ​ | 1,113
Amortization of debt discount and issuance costs | ​ | ​ | 1,031 | ​ | ​ | 1,127 | ​ | ​ | 3,257 | ​ | ​ | 3,437
Letters of credit fees | ​ | ​ | 1,460 | ​ | ​ | 2,488 | ​ | ​ | 5,807 | ​ | ​ | 6,407
Other | ​ | ​ | 246 | ​ | ​ | 167 | ​ | ​ | 626 | ​ | ​ | 576
Total | ​ | $ | 13,074 | ​ | $ | 16,560 | ​ | $ | 41,465 | ​ | $ | 48,910

​

Covenants and Guarantees

The Credit Agreement and Notes contain customary covenants, including restrictions on our restricted subsidiaries’ ability to merge and consolidate with other companies, incur indebtedness, grant liens or security interest on assets, make acquisitions, loans, advances or investments, or sell or otherwise transfer assets. Obligations under the Credit Agreement are secured by a first-priority lien on substantially all of the assets of Adtalem and certain of its domestic wholly-owned subsidiaries. The Credit Agreement contains customary events of default for facilities of this type. If an event of default under the Credit Agreement occurs and is continuing, the commitments thereunder may be terminated and the principal

20

Table of Contents

amount outstanding thereunder, together with all accrued and unpaid interest and other amounts owed thereunder, may be declared immediately due and payable.

Under the terms of the Credit Agreement, Adtalem is required to maintain a Total Net Leverage Ratio (as defined in the Credit Agreement) of equal to or less than 3.25 to 1.00. Adtalem was in compliance with the Credit Agreement debt covenants and the Notes covenants as of March 31, 2025.

14. Share Repurchases

On March 1, 2022, we announced that the Board of Directors (the “Board”) authorized Adtalem’s thirteenth share repurchase program, which allowed Adtalem to repurchase up to $300.0 million of its common stock through February 25, 2025. On January 16, 2024, Adtalem completed its thirteenth share repurchase program. On January 19, 2024, we announced that the Board authorized Adtalem’s fourteenth share repurchase program, which allows Adtalem to repurchase up to $300.0 million of its common stock through January 16, 2027. Adtalem made share repurchases under its share repurchase programs as follows, which include the market price of the shares, commissions, and excise tax (in thousands, except shares and per share data):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Total number of share repurchases | ​ | ​ | 791,420 | ​ | ​ | 1,771,603 | ​ | ​ | 1,724,810 | ​ | ​ | 5,280,736
Total cost of share repurchases | ​ | $ | 77,603 | ​ | $ | 91,409 | ​ | $ | 149,032 | ​ | $ | 252,594
Average price paid per share | ​ | $ | 98.06 | ​ | $ | 51.60 | ​ | $ | 86.40 | ​ | $ | 47.83

​

As of March 31, 2025, $62.5 million of authorized share repurchases were remaining under the fourteenth share repurchase program. On May 5, 2025, Adtalem completed its fourteenth share repurchase program. On May 6, 2025, we announced that the Board of Directors authorized Adtalem’s fifteenth share repurchase program, which allows Adtalem to repurchase up to $150.0 million of its common stock through May 6, 2028. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors. These repurchases may be made through open market purchases, accelerated share repurchases, privately negotiated transactions, or otherwise. Repurchases will be funded through available cash balances and ongoing business operating cash generation and may be suspended or discontinued at any time. Shares of stock repurchased under the programs are held as treasury shares. Repurchases under our share repurchase programs reduce the weighted-average number of shares of common stock outstanding for basic and diluted earnings per share calculations.

​

15. Stock-Based Compensation

Adtalem’s current stock-based incentive plan is its Fourth Amended and Restated Incentive Plan of 2013, which is administered by the Compensation Committee of the Board. Under the plan, employees and directors are eligible to receive stock options, restricted stock units (“RSUs”), performance-based restricted stock units (“PSUs”), and other forms of stock awards. As of March 31, 2025, 1,640,297 shares of common stock were available for future issuance under this plan.

Stock-based compensation expense is recognized on a straight-line basis over the requisite service period. We account for forfeitures of unvested awards in the period they occur. Adtalem issues new shares of common stock to satisfy stock option exercises, RSU vests, and PSU vests. Stock-based compensation expense is included in student services and administrative expense in the Consolidated Statements of Income. There was no capitalized stock-based compensation cost as of March 31, 2025 and June 30, 2024.

Stock Options

Beginning in fiscal year 2023, the Compensation Committee of the Board determined to no longer grant stock options. Prior to fiscal year 2023, we granted stock options generally with a four-year graded vesting from the grant date and expire

21

Table of Contents

ten years from the grant date. The following table summarizes stock option activity for the nine months ended March 31, 2025:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | Weighted-Average | ​ | ​
​ | ​ | Number of | ​ | ​ | ​ | Remaining | ​ | Aggregate
​ | ​ | Stock | ​ | Weighted-Average | ​ | Contractual Life | ​ | Intrinsic Value
​ | ​ | Options | ​ | Exercise Price | ​ | (in years) | ​ | (in thousands)
Outstanding as of June 30, 2024 |  | 550,343 | ​ | $ | 37.34 |  | ​ | ​ | ​ | ​
Exercised |  | (272,960) | ​ | ​ | 36.66 |  | ​ | ​ | ​ | ​
Expired | ​ | (1,325) | ​ | ​ | 36.46 | ​ | ​ | ​ | ​ | ​
Outstanding as of March 31, 2025 |  | 276,058 | ​ |  | 38.01 |  | 5.7 | ​ | $ | 17,289
Exercisable as of March 31, 2025 |  | 233,250 | ​ | $ | 38.19 |  | 5.5 | ​ | $ | 14,566

​

The fair value of stock options that vested during the nine months ended March 31, 2025 and 2024 was $1.3 million and $1.9 million, respectively. As of March 31, 2025, $0.1 million of unrecognized stock-based compensation expense related to unvested stock options is expected to be recognized over a remaining weighted-average period of 0.4 years. The total intrinsic value of stock options exercised for the nine months ended March 31, 2025 and 2024 was $10.6 million and $9.1 million, respectively.

RSUs

Prior to fiscal year 2023, we granted RSUs generally with a four-year graded vesting from the grant date. Beginning in fiscal year 2023, we grant RSUs generally with a three-year graded vesting from the grant date. We also grant RSUs to our Board members with a one-year cliff vest from the grant date. The fair value per share of RSUs is the closing market price of our common stock on the grant date. The following table summarizes RSU activity for the nine months ended March 31, 2025:

​

​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted-Average
​ | ​ | Number of | ​ | Grant Date
​ | ​ | RSUs | ​ | Fair Value
Unvested as of June 30, 2024 |  | 755,841 | ​ | $ | 40.51
Granted |  | 213,390 | ​ |  | 88.99
Vested |  | (348,379) | ​ |  | 40.05
Forfeited |  | (40,870) | ​ |  | 53.00
Unvested as of March 31, 2025 |  | 579,982 | ​ | $ | 57.74

​

The weighted-average grant date fair value per share of RSUs granted in the nine months ended March 31, 2025 and 2024 was $88.99 and $44.23, respectively. The grant date fair value of RSUs that vested during the nine months ended March 31, 2025 and 2024 was $14.0 million and $10.9 million, respectively. As of March 31, 2025, $18.7 million of unrecognized stock-based compensation expense related to unvested RSUs is expected to be recognized over a remaining weighted-average period of 1.8 years.

PSUs

We issue PSUs generally with a three-year cliff vest from the grant date. The fair value per share of PSUs is the closing market price of our common stock on the grant date. We estimate the number of shares that will vest under our PSU awards when recognizing stock-based compensation expense for each reporting period. The final number of shares that vest under

22

Table of Contents

our PSUs is based on metrics approved by the Compensation Committee of the Board. The following table summarizes PSU activity for the nine months ended March 31, 2025:

​

​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Weighted-Average
​ | ​ | Number of | ​ | Grant Date
​ | ​ | PSUs | ​ | Fair Value
Unvested as of June 30, 2024 |  | 629,770 | ​ | $ | 43.77
Granted | ​ | 167,050 | ​ | ​ | 89.74
Vested |  | (83,357) | ​ |  | 33.84
Forfeited |  | (82,443) | ​ |  | 43.65
Unvested as of March 31, 2025 |  | 631,020 | ​ | $ | 57.27

​

The weighted-average grant date fair value per share of PSUs granted in the nine months ended March 31, 2025 and 2024 was $89.74 and $50.07, respectively. The grant date fair value of PSUs that vested during the nine months ended March 31, 2025 and 2024 was $2.8 million and $4.1 million, respectively. As of March 31, 2025, $27.8 million of unrecognized stock-based compensation expense related to unvested PSUs is expected to be recognized over a remaining weighted-average period of 1.7 years.

16. Fair Value Measurements

Fair value is defined under GAAP as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or a liability. The following fair value hierarchy prioritizes the inputs in valuation methodologies used to measure fair value:

Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3 – Unobservable inputs for the asset or liability. These fair value measurements require significant judgement.

The valuation methodologies used for our assets and liabilities measured at fair value and their classification in the valuation hierarchy are described below.

The carrying value of our cash, cash equivalents, and restricted cash approximates fair value because of their short-term nature and is classified as Level 1.

Adtalem maintains a rabbi trust with investments in stock and bond mutual funds to fund obligations under our nonqualified deferred compensation plan. The fair value of the investments in the rabbi trust included in prepaid expenses and other current assets on the Consolidated Balance Sheets as of March 31, 2025 and June 30, 2024 was $11.9 million and $13.2 million, respectively. These investments are recorded at fair value based upon quoted market prices using Level 1 inputs.

The carrying value of the credit extension programs, which approximates its fair value, is included in accounts and financing receivables, net and other assets, net on the Consolidated Balance Sheets as of March 31, 2025 and June 30, 2024 of $26.4 million and $28.9 million, respectively, and is classified as Level 2. See Note 9 “Accounts and Financing Receivables” for additional information on these credit extension programs.

Adtalem has a nonqualified deferred compensation plan for highly compensated employees and its Board members. The participant’s “investments” are in a hypothetical portfolio of investments which are tracked by an administrator. Changes in the fair value of the nonqualified deferred compensation obligation are derived using quoted prices in active markets based on the market price per unit multiplied by the number of units. Total liabilities under the plan included in accrued liabilities on the Consolidated Balance Sheets as of March 31, 2025 and June 30, 2024 were $12.3 million and $12.2 million, respectively. The fair value of the nonqualified deferred compensation obligation is classified as Level 2 because their inputs are derived principally from observable market data by correlation to the hypothetical investments.

23

Table of Contents

As of both March 31, 2025 and June 30, 2024, the principal balance of our Notes was $405.0 million, with a fair value as of those dates of $399.7 million and $389.5 million, respectively. The valuation of the Notes was based upon quoted market prices and is classified as Level 1. As of March 31, 2025 and June 30, 2024, the principal balance of our Term Loan B was $153.3 million and $253.3 million, respectively, with a fair value of $153.7 million and $254.9 million, respectively. The valuation of the Term Loan B was based upon quoted market prices in a non-active market and is classified as Level 2. See Note 13 “Debt” for additional information on our Notes and Term Loan B.

As of June 30, 2024, there were no assets or liabilities measured at fair value using Level 3 inputs.

We recorded asset impairments of $6.4 million on operating lease assets and property and equipment in the three and nine months ended March 31, 2025 as a result of adjusting the respective carrying values to fair values. The fair values were estimated using Level 3 inputs. These impairments were recorded within student services and administrative expense in the Consolidated Statements of Income.

Adtalem has elected not to measure any assets or liabilities at fair value other than those required to be measured at fair value on a recurring basis. Assets measured at fair value on a nonrecurring basis include goodwill, intangible assets, and assets of businesses where the long-term value of the operations are deemed to be impaired. Goodwill and indefinite-lived intangible assets are not amortized, but are reviewed for impairment annually or more frequently if circumstances arise indicating potential impairment. This impairment review was most recently completed as of May 31, 2024. See Note 12 “Goodwill and Intangible Assets” for additional information on the impairment review, including valuation techniques and assumptions.

17. Commitments and Contingencies

Adtalem is subject to lawsuits, administrative proceedings, regulatory reviews, and investigations associated with financial assistance programs and other matters arising in the conduct of its business and certain of these matters are discussed below. Descriptions of certain matters from prior SEC filings may not be carried forward in this report to the extent we believe such matters no longer are required to be disclosed or there has not been, to our knowledge, significant activity relating to them. As of March 31, 2025, we adequately reserved for matters that management has determined a loss is probable and that loss can be reasonably estimated. For those matters for which we have not recorded an accrual, their possible impact on Adtalem’s business, financial condition, or results of operations, cannot be predicted at this time. The continued defense, resolution, or settlement of any of the following matters could require us to expend significant resources and could have a material adverse effect on our business, financial condition, results of operations, and cash flows, and result in the imposition of significant restrictions on us and our ability to operate.

On January 12, 2022, Walden was served with a complaint filed in the United States District Court for the District of Maryland by Aljanal Carroll, Claudia Provost Charles, and Tiffany Fair alleging that Walden has targeted, deceived, and exploited Black and female Doctor of Business Administration (“DBA”) students by knowingly misrepresenting and understating the number of “capstone” credits required to complete the DBA program and obtain a degree. On September 21, 2023, the parties agreed to a $28.5 million payment to resolve the issues in the case. On October 17, 2024, the Court held a fairness hearing, following which, the Court entered an Order granting final approval of the settlement. We recorded a $28.5 million loss contingency accrual for this matter within accrued liabilities on the Consolidated Balance Sheets as of June 30, 2024. On November 27, 2024, Adtalem paid the $28.5 million as required under the settlement agreement. In January 2024, Adtalem made a claim for indemnification under the Membership Interest Purchase Agreement with Laureate Education, Inc. (“Laureate”), dated September 11, 2020, pursuant to which Adtalem purchased Walden. Adtalem received $5.6 million in November 2024 from Laureate in satisfaction of this indemnification claim.

As previously disclosed, pursuant to the terms of the Stock Purchase Agreement (“SPA”) by and between Adtalem and Cogswell, dated as of December 4, 2017, as amended, Adtalem sold DeVry University to Cogswell and Adtalem agreed to indemnify DeVry University for certain losses up to $340.0 million (the “Liability Cap”). Adtalem has previously disclosed DeVry University related matters that have consumed a portion of the Liability Cap.

In late January 2024 and early February 2024, ED sent notice to Chamberlain, RUSM, RUSVM, and Walden that it had received approximately 3,225, 1,700, 1,900, and 7,740 borrower defense to repayment applications filed by students at Chamberlain, RUSM, RUSVM, and Walden respectively between June 23, 2022 and November 15, 2022. Each application

24

Table of Contents

seeks forgiveness of federal student loans made to these students. In the notices received, ED indicated that: (1) the notification was occurring prior to any substantive review of the application as well as its adjudication; (2) it would send the applications to each institution in batches of 500 per week; (3) it is optional for institutions to respond to the applications; and (4) not responding will result in no negative inference by ED. ED has also explained that it will separately decide whether to seek recoupment on any approved claim and that any recoupment actions ED chooses to initiate will have their own notification and response processes, which include an opportunity to provide additional evidence to the institutions. ED has indicated that an institution will learn of ED’s determination to forgive student loans only if it approves a borrower defense to repayment application and ED seeks recoupment. Chamberlain, RUSM, RUSVM, and Walden have responded to all of the applications received and they believe that none properly stated a claim for loan forgiveness.

18. Segment Information

We present three reportable segments as follows:

Chamberlain – This segment includes the operations of Chamberlain, which offers degree and certificate programs in the nursing and health professions postsecondary education industry.

Walden – This segment includes the operations of Walden, which offers degree and certificate programs, including those in nursing, education, counseling, business, psychology, public health, social work and human services, public administration and public policy, and criminal justice.

Medical and Veterinary – This segment includes the operations of AUC, RUSM, and RUSVM, collectively referred to as the “medical and veterinary schools,” which offers degree and certificate programs in the medical and veterinary postsecondary education industry.

These segments are consistent with the method by which the Chief Operating Decision Maker (Adtalem’s Chairman and Chief Executive Officer) evaluates performance and allocates resources. Performance evaluations are based on each segment’s adjusted operating income. Adjusted operating income excludes special items, which consists of restructuring expense, business integration expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs. Adtalem’s management excludes these items from its review of the results of the operating segments for purposes of measuring segment profitability and allocating resources. “Home Office” includes activities not allocated to a reportable segment and is included to reconcile segment results to the Consolidated Financial Statements. Total assets by segment is not presented as our CODM does not review or allocate resources based on segment assets. The accounting policies of the segments are the same as those described in Note 2 “Summary of Significant Accounting Policies.”

25

Table of Contents

Summary financial information by reportable segment is as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Revenue: |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​
Chamberlain | ​ | $ | 192,592 | ​ | $ | 170,338 | ​ | $ | 541,508 | ​ | $ | 466,487
Walden | ​ | ​ | 178,418 | ​ | ​ | 150,607 | ​ | ​ | 511,237 | ​ | ​ | 439,023
Medical and Veterinary | ​ | ​ | 95,045 | ​ | ​ | 91,713 | ​ | ​ | 278,439 | ​ | ​ | 269,235
Total consolidated revenue | ​ | $ | 466,055 | ​ | $ | 412,658 | ​ | $ | 1,331,184 | ​ | $ | 1,174,745
Adjusted operating income: | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ | ​ | ​
Chamberlain | ​ | $ | 47,493 | ​ | $ | 43,349 | ​ | $ | 117,628 | ​ | $ | 97,313
Walden | ​ | ​ | 47,999 | ​ | ​ | 31,871 | ​ | ​ | 136,794 | ​ | ​ | 93,141
Medical and Veterinary | ​ | ​ | 17,921 | ​ | ​ | 22,953 | ​ | ​ | 54,170 | ​ | ​ | 59,521
Home Office | ​ |  | (8,047) | ​ |  | (8,391) | ​ |  | (25,930) | ​ |  | (21,315)
Total consolidated adjusted operating income | ​ | ​ | 105,366 | ​ | ​ | 89,782 | ​ | ​ | 282,662 | ​ | ​ | 228,660
Reconciliation to Consolidated Financial Statements: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring expense | ​ |  | (510) | ​ |  | (473) | ​ |  | (2,926) | ​ |  | (1,217)
Business integration expense | ​ | ​ | — | ​ |  | (18,450) | ​ | ​ | — | ​ |  | (30,621)
Amortization of acquired intangible assets | ​ | ​ | (2,805) | ​ |  | (8,286) | ​ | ​ | (8,415) | ​ |  | (28,296)
Litigation reserve | ​ | ​ | — | ​ |  | — | ​ | ​ | 5,550 | ​ |  | (18,500)
Asset impairments | ​ | ​ | (6,442) | ​ | ​ | — | ​ | ​ | (6,442) | ​ |  | —
Strategic advisory costs | ​ | ​ | (5,100) | ​ | ​ | — | ​ | ​ | (5,100) | ​ |  | —
Loss on assets held for sale | ​ | ​ | — | ​ |  | — | ​ | ​ | — | ​ |  | (647)
Debt modification costs | ​ | ​ | — | ​ |  | (848) | ​ | ​ | (712) | ​ |  | (848)
Total consolidated operating income | ​ | ​ | 90,509 | ​ | ​ | 61,725 | ​ | ​ | 264,617 | ​ | ​ | 148,531
Interest expense | ​ |  | (13,074) | ​ |  | (16,560) | ​ |  | (41,465) | ​ |  | (48,910)
Other income, net | ​ |  | 1,898 | ​ |  | 2,871 | ​ |  | 6,779 | ​ |  | 8,648
Total consolidated income from continuing operations before income taxes | ​ | $ | 79,333 | ​ | $ | 48,036 | ​ | $ | 229,931 | ​ | $ | 108,269
Depreciation: | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​
Chamberlain | ​ | $ | 5,350 | ​ | $ | 4,938 | ​ | $ | 16,184 | ​ | $ | 13,840
Walden | ​ | ​ | 1,951 | ​ | ​ | 1,835 | ​ | ​ | 5,428 | ​ | ​ | 5,735
Medical and Veterinary | ​ | ​ | 2,785 | ​ | ​ | 3,033 | ​ | ​ | 8,098 | ​ | ​ | 8,897
Home Office | ​ |  | 188 | ​ |  | 692 | ​ |  | 557 | ​ |  | 1,407
Total consolidated depreciation | ​ | $ | 10,274 | ​ | $ | 10,498 | ​ | $ | 30,267 | ​ | $ | 29,879
Amortization of acquired intangible assets: | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​
Walden | ​ | $ | 2,805 | ​ | $ | 8,286 | ​ | $ | 8,415 | ​ | $ | 28,296
Total consolidated amortization of acquired intangible assets | ​ | $ | 2,805 | ​ | $ | 8,286 | ​ | $ | 8,415 | ​ | $ | 28,296

​

Adtalem conducts its educational operations in the U.S., Barbados, St. Kitts, and St. Maarten. Revenue by geographic area is as follows (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Revenue by geographic area: |  | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Domestic operations | ​ | $ | 371,010 | ​ | $ | 320,945 | ​ | $ | 1,052,745 | ​ | $ | 905,510
Barbados, St. Kitts, and St. Maarten | ​ |  | 95,045 | ​ |  | 91,713 | ​ |  | 278,439 | ​ |  | 269,235
Total consolidated revenue | ​ | $ | 466,055 | ​ | $ | 412,658 | ​ | $ | 1,331,184 | ​ | $ | 1,174,745

​

No one customer accounted for more than 10% of Adtalem’s consolidated revenue for all periods presented.

26

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This management’s discussion and analysis of financial condition and results of operations (“MD&A”) should be read with and is qualified in its entirety by the Consolidated Financial Statements and the notes thereto included in this report. It should also be read in conjunction with the Cautionary Disclosure Regarding Forward-Looking Statements, the Risk Factors included in or incorporated by reference in this report (see Item 1A. “Risk Factors”), and the Financial Aid and Legislative and Regulatory Requirements disclosures set forth in this report. Adtalem reports on a fiscal year period ending on June 30. Therefore, this Quarterly Report for the quarterly period ended March 31, 2025 is for our third quarter of fiscal year 2025.

Throughout this MD&A, we sometimes use information derived from the Consolidated Financial Statements and the notes thereto but not presented in accordance with U.S. generally accepted accounting principles (“GAAP”). Certain of these items are considered “non-GAAP financial measures” under the Securities and Exchange Commission (“SEC”) rules. See the “Non-GAAP Financial Measures and Reconciliations” section for the reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures.

Certain items presented in tables may not sum due to rounding. Percentages presented are calculated from the underlying numbers in thousands. Discussions throughout this MD&A are based on continuing operations unless otherwise noted. The MD&A should be read in conjunction with the Consolidated Financial Statements and the notes thereto.

Available Information

We use our website (www.adtalem.com) as a routine channel of distribution of company information, including press releases, presentations, and supplemental information, as one means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor our website in addition to following press releases, SEC filings, and public conference calls and webcasts. Investors and others can receive notifications of new information posted on our investor relations website in real time by signing up for email alerts. You may also access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, as well as other reports relating to us that are filed with or furnished to the SEC, free of charge in the investor relations section of our website as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. The SEC also maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov. The content of the websites mentioned above is not incorporated into and should not be considered a part of this report.

Revision of Previously Issued Consolidated Financial Statements

This MD&A has been presented giving effect to the revision discussed in Note 2 “Summary of Significant Accounting Policies” to the Consolidated Financial Statements.

Segments

We present three reportable segments as follows:

Chamberlain – This segment includes the operations of Chamberlain, which offers degree and certificate programs in the nursing and health professions postsecondary education industry.

Walden – This segment includes the operations of Walden, which offers degree and certificate programs, including those in nursing, education, counseling, business, psychology, public health, social work and human services, public administration and public policy, and criminal justice.

Medical and Veterinary – This segment includes the operations of AUC, RUSM, and RUSVM, collectively referred to as the “medical and veterinary schools,” which offers degree and certificate programs in the medical and veterinary postsecondary education industry.

“Home Office” includes activities not allocated to a reportable segment. Financial and descriptive information about Adtalem’s reportable segments is presented in Note 18 “Segment Information” to the Consolidated Financial Statements.

27

Table of Contents

Third Quarter Highlights

Financial and operational highlights for the third quarter of fiscal year 2025 include:

| ● | Adtalem revenue increased 12.9%, or $53.4 million, to $466.1 million in the third quarter of fiscal year 2025 compared to the prior year period driven by increased revenue across all of our segments.

| ● | Net income increased 65.2%, or $24.0 million, to $60.8 million in the third quarter of fiscal year 2025 compared to the prior year period. This increase was primarily driven by an increase in revenue along with decreases in business integration expense and amortization of acquired intangible assets, partially offset by increases in asset impairments, strategic advisory costs, labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, the provision for bad debts, stock-based compensation, and the provision for income taxes.

| ● | Diluted earnings per share increased 71.0%, or $0.66, to $1.59 in the third quarter of fiscal year 2025 compared to the prior year period driven by the increase in net income and lower diluted shares due to share repurchases.

| ● | Adjusted net income increased 23.4%, or $13.9 million, to $73.3 million in the third quarter of fiscal year 2025 compared to the prior year period. This increase was primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, the provision for bad debts, stock-based compensation, and the provision for income taxes.

| ● | Diluted adjusted earnings per share increased 28.0%, or $0.42, to $1.92 in the third quarter of fiscal year 2025 compared to the prior year period driven by the increase in adjusted net income and lower diluted shares due to share repurchases.

| ● | For the January 2025 and March 2025 sessions, total student enrollment at Chamberlain increased 8.7% and 6.8%, respectively, compared to the same sessions last year.

| ● | As of March 31, 2025, total student enrollment at Walden increased 13.5% compared to March 31, 2024.

| ● | For the January 2025 semester, total student enrollment at the medical and veterinary schools increased 1.2% compared to the same semester last year.

| ● | On January 17, 2025, we made a prepayment of $100.0 million on our Term Loan B debt.

| ● | Adtalem repurchased a total of 791,420 shares of its common stock under its share repurchase programs at an average cost of $98.06 per share during the third quarter of fiscal year 2025. On May 5, 2025, Adtalem completed its fourteenth share repurchase program. On May 6, 2025, we announced that the Board of Directors authorized Adtalem’s fifteenth share repurchase program, which allows Adtalem to repurchase up to $150.0 million of its common stock through May 6, 2028. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors.

28

Table of Contents

Results of Operations

Revenue

The following tables present revenue by segment detailing the changes from the prior year periods (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2025 |
​ | ​ | Chamberlain |  | Walden |  | Medical and Veterinary |  | Consolidated |
Fiscal year 2024 | ​ | $ | 170,338 | ​ | $ | 150,607 | ​ | $ | 91,713 | ​ | $ | 412,658 | ​
Growth | ​ | ​ | 22,254 | ​ | ​ | 27,811 | ​ | ​ | 3,332 | ​ | ​ | 53,397 | ​
Fiscal year 2025 | ​ | $ | 192,592 | ​ | $ | 178,418 | ​ | $ | 95,045 | ​ | $ | 466,055 | ​
% change from prior year | ​ | ​ | 13.1 | % | ​ | 18.5 | % | ​ | 3.6 | % | ​ | 12.9 | %

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31, 2025 |
​ | ​ | Chamberlain |  | Walden |  | Medical and Veterinary |  | Consolidated |
Fiscal year 2024 | ​ | $ | 466,487 | ​ | $ | 439,023 | ​ | $ | 269,235 | ​ | $ | 1,174,745 | ​
Growth | ​ | ​ | 75,021 | ​ | ​ | 72,214 | ​ | ​ | 9,204 | ​ | ​ | 156,439 | ​
Fiscal year 2025 | ​ | $ | 541,508 | ​ | $ | 511,237 | ​ | $ | 278,439 | ​ | $ | 1,331,184 | ​
% change from prior year | ​ | ​ | 16.1 | % | ​ | 16.4 | % | ​ | 3.4 | % | ​ | 13.3 | %

​

Chamberlain

Chamberlain Student Enrollment:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal Year 2025 | ​ | ​ | ​
Session | ​ | July 2024 | ​ | Sept. 2024 | ​ | Nov. 2024 | ​ | Jan. 2025 | ​ | Mar. 2025 | ​ | ​ | ​
Total students | ​ | 36,061 | ​ | 38,987 | ​ | 39,691 | ​ | 40,445 | ​ | 40,564 | ​ | ​ | ​
% change from prior year | ​ | 12.1 | % | 11.7 | % | 11.5 | % | 8.7 | % | 6.8 | % | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal Year 2024 | ​
Session | ​ | July 2023 | ​ | Sept. 2023 | ​ | Nov. 2023 | ​ | Jan. 2024 | ​ | Mar. 2024 | ​ | May 2024 |
Total students | ​ | 32,175 | ​ | 34,889 | ​ | 35,592 | ​ | 37,196 | ​ | 37,985 | ​ | 36,750 | ​
% change from prior year | ​ | 2.6 | % | 5.2 | % | 6.6 | % | 7.0 | % | 9.0 | % | 10.4 | %

​

Chamberlain revenue increased 13.1%, or $22.3 million, to $192.6 million in the third quarter and increased 16.1%, or $75.0 million, to $541.5 million in the first nine months of fiscal year 2025 compared to the prior year periods, driven by an increase in enrollment and higher tuition rates. Enrollment improvement has primarily been driven by the undergraduate Bachelor of Science in Nursing (“BSN”) degree and the Master of Science in Nursing (“MSN”) degree programs. Chamberlain is achieving growth by optimizing investments in student enrollment and experience while leveraging scale through a national footprint and providing a full breadth of nursing programs and modalities.

Tuition Rates:

Tuition rates in the current fiscal year increased compared to the prior fiscal year for the BSN onsite and online degree, MSN online degree, and Doctor of Nursing Practice (“DNP”) degree programs. The average increase across all these programs was approximately 4.6% from the prior year.

29

Table of Contents

Walden

Walden Student Enrollment:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal Year 2025 | ​ | ​ | ​
​ | ​ | September 30, | ​ | December 31, | ​ | March 31, | ​ | ​ | ​
Period | ​ | 2024 | ​ | 2024 | ​ | 2025 | ​ | ​ | ​
Total students | ​ | 45,979 | ​ | 46,399 | ​ | 48,526 | ​ | ​ | ​
% change from prior year | ​ | 12.2 | % | 13.2 | % | 13.5 | % | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal Year 2024 | ​
​ | ​ | September 30, | ​ | December 31, | ​ | March 31, | ​ | June 30, | ​
Period | ​ | 2023 | ​ | 2023 | ​ | 2024 | ​ | 2024 | ​
Total students | ​ | 40,975 | ​ | 40,971 | ​ | 42,751 | ​ | 41,845 | ​
% change from prior year | ​ | 0.5 | % | 7.9 | % | 8.4 | % | 11.3 | %

Walden total student enrollment represents those students attending instructional sessions as of the dates identified above. Walden revenue increased 18.5%, or $27.8 million, to $178.4 million in the third quarter and increased 16.4%, or $72.2 million, to $511.2 million in the first nine months of fiscal year 2025 compared to the prior year periods, driven by an increase in enrollment, higher tuition rates, and an increase in average credit hours per student. Walden’s improved enrollment has been accelerated by investments in student experience and brand along with providing flexibility to working adults through part-time and Tempo Learning® competency-based programs.

Tuition Rates:

Tuition rates for Walden programs, including general education are charged on a per credit hour basis that varies based on the nature of the program. For other programs such as those with a subscription-based learning modality, tuition is charged on a per term basis. Students are also charged program and clinical fees depending on the specific programs. Some programs require students to attend residencies, skills labs, and pre-practicum labs, for which tuition is charged per event. In most programs, these tuition rates, event charges, and fees increased by approximately 2% from the prior year.

Medical and Veterinary

Medical and Veterinary Student Enrollment:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal Year 2025 | ​ | ​ | ​
Semester | ​ | Sept. 2024 | ​ | Jan. 2025 | ​ | ​ | ​
Total students | ​ | 5,174 | ​ | 5,133 | ​ | ​ | ​
% change from prior year | ​ | (0.7) | % | 1.2 | % | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal Year 2024 | ​
Semester | ​ | Sept. 2023 | ​ | Jan. 2024 | ​ | May 2024 |
Total students | ​ | 5,209 | ​ | 5,073 | ​ | 4,726 | ​
% change from prior year | ​ | (7.5) | % | (4.5) | % | (2.9) | %

​

Medical and Veterinary revenue increased 3.6%, or $3.3 million, to $95.0 million in the third quarter and increased 3.4%, or $9.2 million, to $278.4 million in the first nine months of fiscal year 2025 compared to the prior year periods, driven by tuition rate increases at all three institutions in this segment. Management’s focus is on increasing enrollment and renewing operational effectiveness, specifically around academic support and the enrollment experience.

Tuition Rates:

| ● | Effective for semesters beginning in September 2024, tuition rates and administrative fees for the beginning basic sciences and clinical rotation portions of AUC’s medical program increased 4.0% and 4.25%, respectively, from the prior academic year.

30

Table of Contents

| ● | Effective for semesters beginning in September 2024, tuition rates and administrative fees for the beginning basic sciences and clinical rotation portions of RUSM’s medical program increased 4.0% and 4.25%, respectively, from the prior academic year.

| ● | Effective for semesters beginning in September 2024, tuition rates for the pre-clinical and clinical curriculum of RUSVM’s veterinary program increased 2.0% from the prior academic year.

Cost of Educational Services

The cost of educational services expense category includes expenses related to the cost of faculty and staff who support educational operations, facilities, adjunct faculty, supplies, housing, bookstore, other educational materials, student education-related support activities, and the provision for bad debts. The following tables present cost of educational services by segment detailing the changes from the prior year periods (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2025 |
​ |  | Chamberlain |  | Walden |  | Medical and Veterinary |  | Consolidated | ​
Fiscal year 2024 |  | $ | 70,565 | ​ | $ | 56,219 |  | $ | 48,537 | ​ | $ | 175,321 | ​
Cost increase |  |  | 12,832 | ​ |  | 5,886 |  |  | 5,830 | ​ |  | 24,548 | ​
Fiscal year 2025 |  | $ | 83,397 | ​ | $ | 62,105 |  | $ | 54,367 | ​ | $ | 199,869 | ​
% change from prior year |  | ​ | 18.2 | % |  | 10.5 | % | ​ | 12.0 | % | ​ | 14.0 | %

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31, 2025 |
​ |  | Chamberlain |  | Walden |  | Medical and Veterinary |  | Consolidated | ​
Fiscal year 2024 |  | $ | 203,244 | ​ | $ | 165,237 |  | $ | 147,527 | ​ | $ | 516,008 | ​
Cost increase |  |  | 33,876 | ​ |  | 12,562 | ​ |  | 10,054 | ​ |  | 56,492 | ​
Fiscal year 2025 |  | $ | 237,120 | ​ | $ | 177,799 |  | $ | 157,581 | ​ | $ | 572,500 | ​
% change from prior year |  | ​ | 16.7 | % |  | 7.6 | % | ​ | 6.8 | % | ​ | 10.9 | %

Cost of educational services increased 14.0%, or $24.5 million, to $199.9 million in the third quarter and increased 10.9%, or $56.5 million, to $572.5 million in the first nine months of fiscal year 2025 compared to the prior year periods. These cost increases were primarily driven by an increase in labor and other costs to support increased enrollment and an increase in the provision for bad debts.

As a percentage of revenue, cost of educational services was 42.9% and 43.0% in the third quarter and first nine months of fiscal year 2025, respectively, compared to 42.5% and 43.9% in the prior year periods. The increase in the percentage for the third quarter of fiscal year 2025 was primarily the result of an increase in the provision for bad debts, partially offset by revenue growth accompanied with cost efficiencies. The decrease in the percentage for the first nine months of fiscal year 2025 was primarily the result of revenue growth accompanied with cost efficiencies, partially offset by an increase in the provision for bad debts.

31

Table of Contents

Student Services and Administrative Expense

The student services and administrative expense category includes expenses related to student admissions, marketing and advertising, general and administrative, and amortization of acquired intangible assets. The following tables present student services and administrative expense by segment detailing the changes from the prior year periods (in thousands):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended March 31, 2025 |
​ |  | Chamberlain |  | Walden |  | Medical and Veterinary |  | Home Office | ​ | Consolidated | ​
Fiscal year 2024 | ​ | $ | 56,425 | ​ | $ | 70,803 | ​ | $ | 20,222 | ​ | $ | 9,239 | ​ | $ | 156,689 | ​
Cost increase (decrease) | ​ |  | 5,277 | ​ |  | 5,797 | ​ |  | 2,535 | ​ |  | (344) | ​ |  | 13,265 | ​
Amortization of acquired intangible assets decrease | ​ | ​ | — | ​ | ​ | (5,481) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (5,481) | ​
Asset impairments increase | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 6,442 | ​ | ​ | 6,442 | ​
Strategic advisory costs increase | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | 5,100 | ​
Debt modification costs decrease | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (848) | ​ | ​ | (848) | ​
Fiscal year 2025 | ​ | $ | 61,702 | ​ | $ | 71,119 | ​ | $ | 22,757 | ​ | $ | 19,589 | ​ | $ | 175,167 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Fiscal year 2025 % change: | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cost increase (decrease) | ​ | ​ | 9.4 | % |  | 8.2 | % | ​ | 12.5 | % |  | NM | ​ | ​ | 8.5 | %
Amortization of acquired intangible assets decrease | ​ |  | — | ​ |  | (7.7) | % |  | — | ​ |  | NM | ​ |  | (3.5) | %
Asset impairments increase | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | NM | ​ | ​ | 4.1 | %
Strategic advisory costs increase | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | NM | ​ | ​ | 3.3 | %
Debt modification costs decrease | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | NM | ​ |  | (0.5) | %
Fiscal year 2025 % change | ​ |  | 9.4 | % |  | 0.4 | % |  | 12.5 | % |  | NM | ​ |  | 11.8 | %

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended March 31, 2025 |
​ |  | Chamberlain |  | Walden |  | Medical and Veterinary |  | Home Office | ​ | Consolidated | ​
Fiscal year 2024 | ​ | $ | 165,930 | ​ | $ | 227,441 | ​ | $ | 62,187 | ​ | $ | 22,810 | ​ | $ | 478,368 | ​
Cost increase | ​ |  | 20,830 | ​ |  | 15,999 | ​ |  | 4,501 | ​ |  | 4,615 | ​ |  | 45,945 | ​
Amortization of acquired intangible assets decrease | ​ | ​ | — | ​ | ​ | (19,881) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (19,881) | ​
Litigation reserve decrease | ​ | ​ | — | ​ | ​ | (24,050) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (24,050) | ​
Asset impairments increase | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 6,442 | ​ | ​ | 6,442 | ​
Strategic advisory costs increase | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | 5,100 | ​
Loss on assets held for sale decrease | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (647) | ​ | ​ | (647) | ​
Debt modification costs decrease | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (136) | ​ | ​ | (136) | ​
Fiscal year 2025 | ​ | $ | 186,760 | ​ | $ | 199,509 | ​ | $ | 66,688 | ​ | $ | 38,184 | ​ | $ | 491,141 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Fiscal year 2025 % change: | ​ |  | ​ | ​ | ​ | ​ | ​ |  | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cost increase | ​ | ​ | 12.6 | % |  | 7.0 | % | ​ | 7.2 | % |  | NM | ​ | ​ | 9.6 | %
Amortization of acquired intangible assets decrease | ​ |  | — | ​ |  | (8.7) | % |  | — | ​ |  | NM | ​ |  | (4.2) | %
Litigation reserve decrease | ​ |  | — | ​ |  | (10.6) | % |  | — | ​ |  | NM | ​ |  | (5.0) | %
Asset impairments increase | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | NM | ​ |  | 1.3 | %
Strategic advisory costs increase | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | NM | ​ |  | 1.1 | %
Loss on assets held for sale decrease | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | NM | ​ |  | (0.1) | %
Debt modification costs decrease | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | NM | ​ |  | (0.0) | %
Fiscal year 2025 % change | ​ |  | 12.6 | % |  | (12.3) | % |  | 7.2 | % |  | NM | ​ |  | 2.7 | %

Student services and administrative expense increased 11.8%, or $18.5 million, to $175.2 million in the third quarter and increased 2.7%, or $12.8 million, to $491.1 million in the first nine months of fiscal year 2025 compared to the prior year periods. After excluding amortization of acquired intangible assets, asset impairments, strategic advisory costs, and

32

Table of Contents

debt modification costs, student services and administrative expense increased 8.5%, or $13.3 million, in the third quarter of fiscal year 2025 compared to the prior year period. After excluding amortization of acquired intangible assets, litigation reserves, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs, student services and administrative expense increased 9.6%, or $45.9 million, in the first nine months of fiscal year 2025 compared to the prior year period. These increases were primarily driven by an increase in marketing expense, investments to support growth initiatives, and stock-based compensation.

As a percentage of revenue, student services and administrative expense was 37.6% and 36.9% in the third quarter and first nine months of fiscal year 2025, respectively, compared to 38.0% and 40.7% in the prior year periods. The decreases in the percentages were primarily the result of revenue growth accompanied by decreases in amortization of acquired intangible assets and litigation reserves, partially offset by increases in asset impairments and strategic advisory costs.

Restructuring Expense

Restructuring expense in the third quarter and first nine months of fiscal year 2025 was $0.5 million and $2.9 million, respectively, compared to $0.5 million and $1.2 million in the prior year periods. The increase in the first nine months of fiscal year 2025 was primarily driven by workforce reductions and costs to exit certain course offerings. We continue to incur restructuring expense or reversals related to exited leased space from previous restructuring activities.

Business Integration Expense

Business integration expense in the third quarter and first nine months of fiscal year 2024 was $18.5 million and $30.6 million, respectively. We did not incur business integration expense during the third quarter and first nine months of fiscal year 2025. In the prior year, we incurred costs associated with integrating Walden into Adtalem. In addition, we initiated transformation initiatives to accelerate growth and organizational agility and certain costs relating to the transformation were included in business integration expense in the Consolidated Statements of Income.

33

Table of Contents

Operating Income

The following table presents a reconciliation of operating income (GAAP) to adjusted operating income (non-GAAP) by segment (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Increase/(Decrease) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Increase/(Decrease) | ​
​ | ​ | 2025 | ​ | 2024 | ​ | $ | ​ | % | ​ | ​ | 2025 | ​ | 2024 | ​ | $ | ​ | % | ​
Chamberlain: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income (GAAP) | ​ | $ | 47,516 | ​ | $ | 43,349 | ​ | $ | 4,167 | ​ | 9.6 | % | ​ | $ | 115,716 | ​ | $ | 97,313 | ​ | $ | 18,403 | ​ | 18.9 | %
Restructuring expense | ​ | ​ | (23) | ​ | ​ | — | ​ | ​ | (23) | ​ | ​ | ​ | ​ | ​ | 1,912 | ​ | ​ | — | ​ | ​ | 1,912 | ​ | ​ | ​
Adjusted operating income (non-GAAP) | ​ | $ | 47,493 | ​ | $ | 43,349 | ​ | $ | 4,144 | ​ | 9.6 | % | ​ | $ | 117,628 | ​ | $ | 97,313 | ​ | $ | 20,315 | ​ | 20.9 | %
Operating margin (GAAP) | ​ | ​ | 24.7 | % | ​ | 25.4 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 21.4 | % | ​ | 20.9 | % | ​ | ​ | ​ | ​ | ​
Operating margin (non-GAAP) | ​ | ​ | 24.7 | % | ​ | 25.4 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 21.7 | % | ​ | 20.9 | % | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Walden: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income (GAAP) | ​ | $ | 45,194 | ​ | $ | 23,585 | ​ | $ | 21,609 | ​ | 91.6 | % | ​ | $ | 133,929 | ​ | $ | 47,121 | ​ | $ | 86,808 | ​ | 184.2 | %
Restructuring expense | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | (776) | ​ | ​ | 776 | ​ | ​ | ​
Amortization of acquired intangible assets | ​ | ​ | 2,805 | ​ | ​ | 8,286 | ​ | ​ | (5,481) | ​ | ​ | ​ | ​ | ​ | 8,415 | ​ | ​ | 28,296 | ​ | ​ | (19,881) | ​ | ​ | ​
Litigation reserve | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (5,550) | ​ | ​ | 18,500 | ​ | ​ | (24,050) | ​ | ​ | ​
Adjusted operating income (non-GAAP) | ​ | $ | 47,999 | ​ | $ | 31,871 | ​ | $ | 16,128 | ​ | 50.6 | % | ​ | $ | 136,794 | ​ | $ | 93,141 | ​ | $ | 43,653 | ​ | 46.9 | %
Operating margin (GAAP) | ​ | ​ | 25.3 | % | ​ | 15.7 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 26.2 | % | ​ | 10.7 | % | ​ | ​ | ​ | ​ | ​
Operating margin (non-GAAP) | ​ | ​ | 26.9 | % | ​ | 21.2 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 26.8 | % | ​ | 21.2 | % | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Medical and Veterinary: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income (GAAP) | ​ | $ | 17,800 | ​ | $ | 22,759 | ​ | $ | (4,959) | ​ | (21.8) | % | ​ | $ | 53,934 | ​ | $ | 59,142 | ​ | $ | (5,208) | ​ | (8.8) | %
Restructuring expense | ​ | ​ | 121 | ​ | ​ | 194 | ​ | ​ | (73) | ​ | ​ | ​ | ​ | ​ | 236 | ​ | ​ | 379 | ​ | ​ | (143) | ​ | ​ | ​
Adjusted operating income (non-GAAP) | ​ | $ | 17,921 | ​ | $ | 22,953 | ​ | $ | (5,032) | ​ | (21.9) | % | ​ | $ | 54,170 | ​ | $ | 59,521 | ​ | $ | (5,351) | ​ | (9.0) | %
Operating margin (GAAP) | ​ | ​ | 18.7 | % | ​ | 24.8 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 19.4 | % | ​ | 22.0 | % | ​ | ​ | ​ | ​ | ​
Operating margin (non-GAAP) | ​ | ​ | 18.9 | % | ​ | 25.0 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 19.5 | % | ​ | 22.1 | % | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Home Office: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating loss (GAAP) | ​ | $ | (20,001) | ​ | $ | (27,968) | ​ | $ | 7,967 | ​ | 28.5 | % | ​ | $ | (38,962) | ​ | $ | (55,045) | ​ | $ | 16,083 | ​ | 29.2 | %
Restructuring expense | ​ | ​ | 412 | ​ | ​ | 279 | ​ | ​ | 133 | ​ | ​ | ​ | ​ | ​ | 778 | ​ | ​ | 1,614 | ​ | ​ | (836) | ​ | ​ | ​
Business integration expense | ​ | ​ | — | ​ | ​ | 18,450 | ​ | ​ | (18,450) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | 30,621 | ​ | ​ | (30,621) | ​ | ​ | ​
Asset impairments | ​ | ​ | 6,442 | ​ | ​ | — | ​ | ​ | 6,442 | ​ | ​ | ​ | ​ | ​ | 6,442 | ​ | ​ | — | ​ | ​ | 6,442 | ​ | ​ | ​
Strategic advisory costs | ​ | ​ | 5,100 | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | ​ | ​ | ​ | 5,100 | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | ​
Loss on assets held for sale | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | 647 | ​ | ​ | (647) | ​ | ​ | ​
Debt modification costs | ​ | ​ | — | ​ | ​ | 848 | ​ | ​ | (848) | ​ | ​ | ​ | ​ | ​ | 712 | ​ | ​ | 848 | ​ | ​ | (136) | ​ | ​ | ​
Adjusted operating loss (non-GAAP) | ​ | $ | (8,047) | ​ | $ | (8,391) | ​ | $ | 344 | ​ | 4.1 | % | ​ | $ | (25,930) | ​ | $ | (21,315) | ​ | $ | (4,615) | ​ | (21.7) | %
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Adtalem Global Education: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income (GAAP) | ​ | $ | 90,509 | ​ | $ | 61,725 | ​ | $ | 28,784 | ​ | 46.6 | % | ​ | $ | 264,617 | ​ | $ | 148,531 | ​ | $ | 116,086 | ​ | 78.2 | %
Restructuring expense | ​ | ​ | 510 | ​ | ​ | 473 | ​ | ​ | 37 | ​ | ​ | ​ | ​ | ​ | 2,926 | ​ | ​ | 1,217 | ​ | ​ | 1,709 | ​ | ​ | ​
Business integration expense | ​ | ​ | — | ​ | ​ | 18,450 | ​ | ​ | (18,450) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | 30,621 | ​ | ​ | (30,621) | ​ | ​ | ​
Amortization of acquired intangible assets | ​ | ​ | 2,805 | ​ | ​ | 8,286 | ​ | ​ | (5,481) | ​ | ​ | ​ | ​ | ​ | 8,415 | ​ | ​ | 28,296 | ​ | ​ | (19,881) | ​ | ​ | ​
Litigation reserve | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (5,550) | ​ | ​ | 18,500 | ​ | ​ | (24,050) | ​ | ​ | ​
Asset impairments | ​ | ​ | 6,442 | ​ | ​ | — | ​ | ​ | 6,442 | ​ | ​ | ​ | ​ | ​ | 6,442 | ​ | ​ | — | ​ | ​ | 6,442 | ​ | ​ | ​
Strategic advisory costs | ​ | ​ | 5,100 | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | ​ | ​ | ​ | 5,100 | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | ​
Loss on assets held for sale | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | 647 | ​ | ​ | (647) | ​ | ​ | ​
Debt modification costs | ​ | ​ | — | ​ | ​ | 848 | ​ | ​ | (848) | ​ | ​ | ​ | ​ | ​ | 712 | ​ | ​ | 848 | ​ | ​ | (136) | ​ | ​ | ​
Adjusted operating income (non-GAAP) | ​ | $ | 105,366 | ​ | $ | 89,782 | ​ | $ | 15,584 | ​ | 17.4 | % | ​ | $ | 282,662 | ​ | $ | 228,660 | ​ | $ | 54,002 | ​ | 23.6 | %
Operating margin (GAAP) | ​ | ​ | 19.4 | % | ​ | 15.0 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 19.9 | % | ​ | 12.6 | % | ​ | ​ | ​ | ​ | ​
Operating margin (non-GAAP) | ​ | ​ | 22.6 | % | ​ | 21.8 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 21.2 | % | ​ | 19.5 | % | ​ | ​ | ​ | ​ | ​

Consolidated operating income increased 46.6%, or $28.8 million, to $90.5 million in the third quarter and increased 78.2%, or $116.1 million, to $264.6 million in the first nine months of fiscal year 2025 compared to the prior year periods. The operating income increase in the third quarter of fiscal year 2025 was primarily driven by an increase in revenue and decreases in business integration expense and amortization of acquired intangible assets, partially offset by increases in asset impairments, strategic advisory costs, labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, the provision for bad debts, and stock-based compensation. The operating

34

Table of Contents

income increase in the first nine months of fiscal year 2025 was primarily driven by an increase in revenue and decreases in business integration expense, amortization of acquired intangible assets, and litigation reserves, partially offset by increases in asset impairments, strategic advisory costs, labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, the provision for bad debts, and stock-based compensation. The decreases in amortization of acquired intangible assets are driven by the decreases in amortization relating to the Walden student relationships intangible asset, which was fully amortized as of June 30, 2024. The decrease in litigation reserves includes a $5.6 million receipt in the second quarter of fiscal year 2025 from a claim made for indemnification under the Membership Interest Purchase Agreement with Laureate Education, Inc.

Consolidated adjusted operating income increased 17.4%, or $15.6 million, to $105.4 million in the third quarter and increased 23.6%, or $54.0 million, to $282.7 million in the first nine months of fiscal year 2025 compared to the prior year periods. The adjusted operating income increases in the third quarter and first nine months of fiscal year 2025 were primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, the provision for bad debts, and stock-based compensation.

Chamberlain

Chamberlain operating income increased 9.6%, or $4.2 million, to $47.5 million in the third quarter and increased 18.9%, or $18.4 million, to $115.7 million in the first nine months of fiscal year 2025 compared to the prior year periods. Segment adjusted operating income increased 9.6%, or $4.1 million, to $47.5 million in the third quarter and increased 20.9%, or $20.3 million, to $117.6 million in the first nine months of fiscal year 2025 compared to the prior year periods. The adjusted operating income increases in the third quarter and first nine months of fiscal year 2025 were primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, investments to support growth initiatives, and the provision for bad debts.

Walden

Walden operating income increased 91.6%, or $21.6 million, to $45.2 million in the third quarter and increased 184.2%, or $86.8 million, to $133.9 million in the first nine months of fiscal year 2025 compared to the prior year periods. Segment adjusted operating income increased 50.6%, or $16.1 million, to $48.0 million in the third quarter and increased 46.9%, or $43.7 million, to $136.8 million in the first nine months of fiscal year 2025 compared to the prior year periods. The adjusted operating income increases in the third quarter and first nine months of fiscal year 2025 were primarily driven by an increase in revenue, partially offset by increases in labor and other costs to support increased enrollment, marketing expense, and investments to support growth initiatives.

Medical and Veterinary

Medical and Veterinary operating income decreased 21.8%, or $5.0 million, to $17.8 million in the third quarter and decreased 8.8%, or $5.2 million, to $53.9 million in the first nine months of fiscal year 2025 compared to the prior year periods. Segment adjusted operating income decreased 21.9%, or $5.0 million, to $17.9 million in the third quarter and decreased 9.0%, or $5.4 million, to $54.2 million in the first nine months of fiscal year 2025 compared to the prior year periods. The adjusted operating income decreases in the third quarter and first nine months of fiscal year 2025 were primarily driven by increases in investments to support initiatives to drive future growth, investments in academic support, and the provision for bad debts, partially offset by increases in revenue.

Interest Expense

Interest expense in the third quarter and first nine months of fiscal year 2025 was $13.1 million and $41.5 million, respectively, compared to $16.6 million and $48.9 million in the prior year periods. The interest expense decreases in the third quarter and first nine months of fiscal year 2025 was primarily driven by lower interest expense on our Term Loan B due to decreased borrowings and a lower interest rate (as discussed in Note 13 “Debt” to the Consolidated Financial Statements).

35

Table of Contents

Other Income, Net

Other income, net in the third quarter and first nine months of fiscal year 2025 was income of $1.9 million and income of $6.8 million, respectively, compared to income of $2.9 million and income of $8.6 million in the prior year periods. These decreases were primarily driven by decreases in interest income and investment income.

Provision for Income Taxes

Our effective income tax rate from continuing operations can differ from the 21% U.S. federal statutory rate due to several factors, including tax on global intangible low-taxed income (“GILTI”), limitation of tax benefits on certain executive compensation, the rate of tax applied by state and local jurisdictions, the rate of tax applied to earnings outside the U.S., tax incentives, tax credits related to research and development expenditures, changes in valuation allowance, changes in uncertain tax positions, and tax benefits on stock-based compensation awards.

Our effective tax rate from continuing operations was 23.4% and 22.5% in the three and nine months ended March 31, 2025, respectively, and 22.1% and 19.5% in the three and nine months ended March 31, 2024, respectively. The effective tax rate for the three and nine months ended March 31, 2025 increased compared to the prior year periods primarily due to an increase in the percentage of earnings from operations in higher taxed jurisdictions and a limitation of tax benefits on certain executive compensation.

Discontinued Operations

We had income from discontinued operations in the third quarter of fiscal year 2025 of $0.04 million and income of $4.6 million in the first nine months of fiscal year 2025, compared to a loss in the third quarter of fiscal year 2024 of $0.6 million and income of $0.2 million in the first nine months of fiscal year 2024. We recorded income within discontinued operations related to the DeVry University earn-out of $7.0 million and $5.5 million in the first nine months of fiscal year 2025 and 2024, respectively. In addition, we continue to incur costs associated with ongoing litigation and settlements related to divestitures, which are classified as expenses within discontinued operations.

Financial Aid

Like other higher education institutions, Adtalem’s institutions are dependent upon the timely receipt of federal financial aid funds. All public financial aid programs are subject to political and governmental budgetary considerations. Adtalem’s institutions and their students participate in a wide range of financial aid programs, including U.S. federal financial aid, state financial aid, Canadian financial aid, private loan programs, tax-favored programs, Adtalem-provided financial assistance, and employer-provided financial assistance. In the U.S., the Higher Education Act (as reauthorized, the “HEA”) guides the federal government’s support of postsecondary education. If there are changes to financial aid programs that restrict student eligibility or reduce funding levels, Adtalem’s financial condition and cash flows could be materially and adversely affected. See Item 1A. “Risk Factors” in our 2024 Form 10-K.

Legislative and Regulatory Requirements

Government-funded financial assistance programs are governed by extensive and complex regulations in the U.S. Like any other educational institution, Adtalem’s institutions’ administration of these programs is periodically reviewed by regulatory agencies and is subject to audit or investigation by other authorities. Any violation could be the basis for penalties or other disciplinary action, including initiation of a suspension, limitation, or termination proceeding.

Financial Responsibility

Institutions must pass a U.S. Department of Education (“ED”) financial responsibility test, also known as a “composite score,” to maintain eligibility to participate in Title IV aid programs. For Adtalem’s institutions, this test is calculated at the consolidated Adtalem level. Applying various financial elements from annual audited financial statements, the score is a composite of three ratios: an equity ratio that measures the institution’s capital resources; a primary reserve ratio that measures an institution’s ability to fund its operations from current resources; and a net income ratio that measures an institution’s ability to operate profitably. A score greater than or equal to 1.5 indicates the institution is considered financially responsible. A score less than 1.5 but greater than or equal to 1.0 is considered financially responsible but

36

Table of Contents

requires additional oversight. For example, an institution with a score in this range is subject to heightened cash monitoring and other participation requirements. An institution with a score of less than 1.0 is not considered financially responsible but may continue to participate in the Title IV programs under provisional certification. In addition, this lower score typically requires that the institution be subject to heightened cash monitoring requirements and post a letter of credit (equal to a minimum of 10% of the Title IV aid it received in the institution's most recent fiscal year).

Prior to fiscal year 2022, Adtalem’s composite score was greater than 1.5. However, on September 25, 2023, ED notified Adtalem that its fiscal year 2022 composite score had declined to 0.2. As previously disclosed, this was expected due to the acquisition of Walden and other transactions. ED advised that Adtalem’s five institutions will be permitted to continue to participate in Title IV under provisional certifications with heightened cash monitoring and continued reporting. A letter of credit in the amount of $157.9 million, representing 10% of the consolidated Title IV funds Adtalem’s institutions received during fiscal year 2022, was delivered to ED on November 1, 2023 with an expiration date of December 31, 2024. On December 3, 2024, ED requested Adtalem amend the letter of credit to $179.0 million, representing 10% of the consolidated Title IV funds Adtalem’s institutions received during fiscal year 2024 with an expiration date of January 31, 2026. As requested, Adtalem delivered this amended letter of credit to ED on December 13, 2024. Adtalem satisfied this request by securing a $99.0 million letter of credit under its Revolver and an $80.0 million surety-backed letter of credit. In February 2025, Adtalem replaced the $99.0 million letter of credit under its Revolver with a $99.0 million surety-backed letter of credit. Management does not believe these conditions will have a material adverse effect on Adtalem’s operations.

The financial responsibility rules include other mandatory or discretionary triggers that could require an institution to post a letter of credit. ED recently amended the financial responsibility regulation and the changes took effect July 1, 2024. The changes include additional triggers which could require additional letters of credit.

Program Participation Agreement (“PPA”)

All institutions must apply periodically to ED for continued certification to participate in Title IV programs. Such recertification generally is required every six years, but may be required earlier, including when an institution undergoes a change in control. ED may place an institution on provisional certification status if it finds that the institution does not fully satisfy all of the eligibility and certification standards and in certain other circumstances, such as when an institution is certified for the first time or undergoes a change in control. During the period of provisional certification, the institution must comply with any additional conditions included in the institution’s PPA. In addition, ED may more closely review an institution that is provisionally certified if it applies for recertification or approval to open a new location, add an educational program, acquire another institution, or make any other significant change. Students attending provisionally certified institutions remain eligible to receive Title IV program funds. If ED determines that a provisionally certified institution is unable to meet its responsibilities under its PPA, it may seek to revoke the institution’s certification to participate in Title IV programs without advance notice or opportunity for the institution to challenge the action.

Chamberlain was most recently recertified and issued an unrestricted PPA in September 2020, with a reapplication date of June 30, 2024. The lengthy PPA recertification process is such that ED allows unhampered continued access to Title IV funding after PPA expiration, so long as materially complete applications are submitted at least 90 days in advance of expiration. A complete application for Chamberlain’s PPA recertification has been timely submitted to ED.

ED approved Walden’s change in ownership application and issued Walden a provisional PPA through June 30, 2025, with its application for PPA recertification due March 31, 2025. A complete application for Walden’s PPA recertification has been timely submitted to ED.

ED provisionally recertified AUC and RUSM’s Title IV PPAs through March 31, 2025. Complete applications for AUC and RUSM’s PPA recertification have been timely submitted to ED. ED has provisionally recertified RUSVM’s Title IV PPA through March 31, 2027.

The provisional nature of the PPAs stemmed from Adtalem’s composite score declining and failing to meet ED’s standards of financial responsibility as described above.

Walden, AUC, RUSM, and RUSVM’s provisional PPAs included financial requirements, such as letter of credit, heightened cash monitoring, and additional reporting. We do not believe these requirements will have a material effect on

37

Table of Contents

Adtalem’s financial position or results of operations. With the approval of its change in ownership, Walden has the ability to request ED approval for new programs.

As of March 31, 2025, Adtalem had $179.0 million of letters of credit outstanding in favor of ED. See “Off-Balance Sheet Arrangements” in Note 13 “Debt” to the Consolidated Financial Statements for additional information.

Gainful Employment

The HEA requires certificate programs at all Title IV institutions and degree programs at proprietary Title IV institutions to prepare students for gainful employment in a recognized occupation. In October 2023, ED released new Financial Value Transparency (“FVT”) and Gainful Employment (“GE”) rules effective July 1, 2024. GE programs must meet a debt-to-earnings test in which graduates’ annual debt payments must not exceed 8% of their annual earnings or 20% of their discretionary earnings. GE programs must also meet an earnings premium test in which graduates’ earnings must exceed those of a typical high school graduate. Under the regulation, programs that fail either metric must provide warnings to students and prospective students that the program is at risk of losing Title IV eligibility and programs that fail the same measure in two out of three consecutive years lose Title IV eligibility. The GE regulation also includes a transparency framework in which debt-to-earnings, earnings premium, and a wide range of other program outcomes for all Title IV programs are disclosed on a website hosted by ED. Because there are many factors and unknowns, including the earnings of program graduates, Adtalem is reviewing the regulation to determine what impact, if any, the regulation will have on its programs. In addition, multiple parties are seeking to block enforcement of the FVT/GE rule under the Administrative Procedure Act and other legal theories. On February 14, 2025, ED extended the institutional reporting deadline until September 30, 2025.

The “90/10 Rule”

An ED regulation known as the “90/10 Rule” affects only proprietary institutions participating in Title IV programs, including each of Adtalem’s institutions. An institution that does not meet the 90% threshold for two consecutive fiscal years loses its eligibility to participate in Title IV programs. Previously, an institution could not derive more than 90% of its revenue on a cash basis from Title IV financial aid funds. In March 2021, the American Rescue Plan Act amended the 90/10 calculation to require no more than 90% of revenue at proprietary institutions be derived from any federal education assistance funds, including but not limited to previously excluded U.S. Department of Veterans Affairs benefits and Department of Defense tuition assistance funds. This change was subject to negotiated rulemaking with the final rule published by ED in October 2022. The amended rule applies to an institution’s fiscal years beginning on or after January 1, 2023. For Adtalem’s institutions, the updated 90/10 rule is therefore effective with the calculation for fiscal year 2024. The following table shows the 90/10 rates for each Adtalem institution for fiscal year 2024 based on the new 90/10 rules and fiscal year 2023 based on the old 90/10 rules that were still in effect for that period. We are also providing a consolidated rate for Adtalem even though it is not subject to 90/10 requirements.

​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal Year |
​ | ​ | 2024 | ​ | 2023 |
Chamberlain University |  | 68 | % | 65 | %
Walden University |  | 82 | % | 78 | %
American University of the Caribbean School of Medicine |  | 87 | % | 81 | %
Ross University School of Medicine |  | 87 | % | 87 | %
Ross University School of Veterinary Medicine |  | 78 | % | 79 | %
Consolidated |  | 77 | % | 75 | %

Liquidity and Capital Resources

Adtalem’s primary source of liquidity is the cash received from payments for student tuition, fees, books, and other educational materials. These payments include funds originating as financial aid from various federal and state loan and grant programs, student and family educational loans, employer educational reimbursements, scholarships, and student and family financial resources. Adtalem continues to provide financing options for its students, including Adtalem’s credit extension programs.

38

Table of Contents

The pattern of cash receipts during the year is seasonal. Adtalem’s cash collections on accounts receivable peak at the start of each institution’s term. Accounts receivable reach their lowest level at the end of each institution’s term.

Adtalem’s consolidated cash and cash equivalents balance of $219.0 million and $219.3 million as of March 31, 2025 and June 30, 2024, respectively, included cash and cash equivalents held at Adtalem’s international operations of $4.1 million and $4.6 million as of March 31, 2025 and June 30, 2024, respectively, which is available to Adtalem for general corporate purposes.

Cash Flow Summary

Operating Activities

Net cash provided by operating activities from continuing operations in the nine months ended March 31, 2025 increased $46.7 million to $273.8 million, compared to $227.1 million in the prior year period. This increase was driven by a $116.1 million increase in operating income primarily due to increased revenue from students. The increase in cash provided by operating activities from continuing operations was partially offset by a $22.9 million increase in net legal settlement payments, a $20.3 million increase in management incentive bonus payments, and a $35.2 million increase in payments to vendors.

Investing Activities

Net cash used in investing activities in the nine months ended March 31, 2025 and 2024 was $30.3 million and $32.2 million, respectively, and was primarily driven by capital expenditures of $31.3 million and $32.3 million, respectively. The capital expenditures in fiscal year 2025 primarily consisted of spending for information technology investments and Chamberlain’s campus development. For the remainder of fiscal year 2025, we expect capital spending on information technology, new campus development at Chamberlain, and facility improvements at the medical and veterinary schools. Management anticipates full fiscal year 2025 capital spending to be in the $40 to $50 million range. The source of funds for this capital spending will be from operations or the Credit Facility (as defined and discussed in Note 13 “Debt” to the Consolidated Financial Statements).

Financing Activities

Net cash used in financing activities in the nine months ended March 31, 2025 and 2024 was $248.0 million and $291.1 million, respectively, and was primarily driven by share repurchases of $146.4 million and $250.5 million, respectively, and net long-term debt repayments of $100.0 million and $50.0 million, respectively.

On March 1, 2022, we announced that the Board authorized Adtalem’s thirteenth share repurchase program, which allowed Adtalem to repurchase up to $300.0 million of its common stock through February 25, 2025. On January 16, 2024, Adtalem completed its thirteenth share repurchase program. On January 19, 2024, we announced that the Board authorized Adtalem’s fourteenth share repurchase program, which allows Adtalem to repurchase up to $300.0 million of its common stock through January 16, 2027. As of March 31, 2025, $62.5 million of authorized share repurchases were remaining under the fourteenth share repurchase program. On May 5, 2025, Adtalem completed its fourteenth share repurchase program. On May 6, 2025, we announced that the Board of Directors authorized Adtalem’s fifteenth share repurchase program, which allows Adtalem to repurchase up to $150.0 million of its common stock through May 6, 2028. The timing and amount of any future repurchases will be determined based on an evaluation of market conditions and other factors. See Note 14 “Share Repurchases” to the Consolidated Financial Statements for additional information on our share repurchase programs.

On March 1, 2021, we issued $800.0 million aggregate principal amount of 5.50% Senior Secured Notes due 2028 (the “Notes”), which mature on March 1, 2028. On August 12, 2021, Adtalem entered into its new credit agreement (the “Credit Agreement”) that provides for (1) a $850.0 million senior secured term loan (“Term Loan B”) with a maturity date of August 12, 2028 and (2) a $400.0 million senior secured revolving loan facility (“Revolver”) with a maturity date of August 12, 2026. We refer to the Term Loan B and Revolver collectively as the “Credit Facility.” As of March 31, 2025, the principal balance of the Notes and Term Loan B was $405.0 million and $153.3 million, respectively. See Note 13 “Debt” to the Consolidated Financial Statements for additional information on the Notes and our Credit Agreement.

39

Table of Contents

In the event of unexpected market conditions or negative economic changes that could negatively affect Adtalem’s earnings and/or operating cash flow, Adtalem maintains a $400.0 million revolving credit facility with availability of $400.0 million as of March 31, 2025.

Material Cash Requirements

Long-Term Debt – As of March 31, 2025, we have principal balances of $405.0 million of Notes and $153.3 million of Term Loan B, which requires interest payments. With previous Term Loan B prepayments, we are no longer required to make quarterly principal installment payments on the Term Loan B. See Note 13 “Debt” to the Consolidated Financial Statements for additional information on the Notes and our Credit Agreement.

As of March 31, 2025, Adtalem had $179.0 million of letters of credit outstanding in favor of ED. See “Off-Balance Sheet Arrangements” in Note 13 “Debt” to the Consolidated Financial Statements for additional information.

Many states require private-sector postsecondary education institutions to post surety bonds for licensure. In the U.S., Adtalem has posted $66.5 million of surety bonds as of March 31, 2025 with regulatory authorities on behalf of Chamberlain, Walden, AUC, RUSM, and RUSVM.

Operating Lease Obligations – We have operating lease obligations for the minimum payments required under various lease agreements which are recorded on the Consolidated Balance Sheets. In addition, we sublease certain space to third parties, which partially offsets the lease obligations at these facilities. See Note 11 “Leases” to the Consolidated Financial Statements for additional information on our lease agreements.

Critical Accounting Estimates

There have been no material changes in our critical accounting estimates as disclosed in our 2024 Form 10-K.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, see Note 2 “Summary of Significant Accounting Policies” to the Consolidated Financial Statements.

Cautionary Disclosure Regarding Forward-Looking Statements

Certain statements contained in this Quarterly Report on Form 10-Q are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, which includes statements regarding Adtalem’s future growth. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “future,” “believe,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “may,” “will,” “would,” “could,” “can,” “continue,” “preliminary,” “range,” and similar terms. These forward-looking statements are subject to risk and uncertainties that could cause actual results to differ materially from those described in the statements. These risks and uncertainties include the risk factors described in Item 1A. “Risk Factors” of our 2024 Form 10-K and that might be contained in this Quarterly Report on Form 10-Q, which should be read in conjunction with the forward-looking statements in this Quarterly Report on Form 10-Q. These forward-looking statements are based on information available to us as of the date any such statements are made, and Adtalem assumes no obligation to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized, except as required by law.

Non-GAAP Financial Measures and Reconciliations

We believe that certain non-GAAP financial measures provide investors with useful supplemental information regarding the underlying business trends and performance of Adtalem’s ongoing operations as seen through the eyes of management and are useful for period-over-period comparisons. We use these supplemental non-GAAP financial measures internally in our assessment of performance and budgeting process. However, these non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The following are non-GAAP financial measures used in this Quarterly Report on Form 10-Q:

40

Table of Contents

Adjusted net income (most comparable GAAP measure: net income) – Measure of Adtalem’s net income adjusted for restructuring expense, business integration expense, amortization of acquired intangible assets, write-off of debt discount and issuance costs, litigation reserve, asset impairments, loss on assets held for sale, debt modification costs, strategic advisory costs, and (income) loss from discontinued operations.

Adjusted earnings per share (most comparable GAAP measure: diluted earnings per share) – Measure of Adtalem’s diluted earnings per share adjusted for restructuring expense, business integration expense, amortization of acquired intangible assets, write-off of debt discount and issuance costs, litigation reserve, asset impairments, loss on assets held for sale, debt modification costs, strategic advisory costs, and (income) loss from discontinued operations.

Adjusted operating income (most comparable GAAP measure: operating income) – Measure of Adtalem’s operating income adjusted for restructuring expense, business integration expense, amortization of acquired intangible assets, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs. This measure is applied on a consolidated and segment basis, depending on the context of the discussion.

Adjusted EBITDA (most comparable GAAP measure: net income) – Measure of Adtalem’s net income adjusted for (income) loss from discontinued operations, interest expense, other income, net, provision for income taxes, depreciation, amortization of acquired intangible assets, amortization of cloud computing implementation assets, stock-based compensation, restructuring expense, business integration expense, litigation reserve, asset impairments, strategic advisory costs, loss on assets held for sale, and debt modification costs. This measure is applied on a consolidated and segment basis, depending on the context of the discussion. Provision for income taxes, interest expense, and other income, net is not recorded at the reportable segments, and therefore, the segment adjusted EBITDA reconciliations begin with operating income.

A description of special items in our non-GAAP financial measures described above are as follows:

| ● | Restructuring expense primarily related to workforce reductions, costs to exit certain course offerings, and prior real estate consolidations at Adtalem’s home office. We do not include normal, recurring, cash operating expenses in our restructuring expense.

| ● | Business integration expense includes expenses related to the Walden acquisition and certain costs related to growth transformation initiatives. We do not include normal, recurring, cash operating expenses in our business integration expense.

| ● | Amortization of acquired intangible assets.

| ● | Amortization of cloud computing implementation assets.

| ● | Write-off of debt discount and issuance costs related to prepayments of debt, reserves related to significant litigation, asset impairments related to adjusting certain operating lease assets and property and equipment as a result of adjusting carrying values to fair values, loss on assets held for sale related to adjusting those assets to estimated fair value less costs to sell, and debt modification costs related to refinancing our Term Loan B loan.

| ● | Strategic advisory costs related to expanding capabilities and bringing new capacities to market to further enhance our strategic position. We do not include normal, recurring, cash operating expenses in our strategic advisory costs.

| ● | (Income) loss from discontinued operations includes expense from ongoing litigation costs and settlements related to divestitures and the earn-outs we received.

The following tables provide a reconciliation from the most directly comparable GAAP measure to these non-GAAP financial measures. The operating income reconciliation is included in the results of operations section within this MD&A.

41

Table of Contents

Net income reconciliation to adjusted net income (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Net income (GAAP) | ​ | $ | 60,832 | ​ | $ | 36,821 | ​ | $ | 182,853 | ​ | $ | 87,358
Restructuring expense | ​ | ​ | 510 | ​ | ​ | 473 | ​ | ​ | 2,926 | ​ | ​ | 1,217
Business integration expense | ​ | ​ | — | ​ | ​ | 18,450 | ​ | ​ | — | ​ | ​ | 30,621
Amortization of acquired intangible assets | ​ | ​ | 2,805 | ​ | ​ | 8,286 | ​ | ​ | 8,415 | ​ | ​ | 28,296
Write-off of debt discount and issuance costs, litigation reserve, asset impairments, loss on assets held for sale, and debt modification costs | ​ | ​ | 8,180 | ​ | ​ | 1,961 | ​ | ​ | 3,342 | ​ | ​ | 21,108
Strategic advisory costs | ​ | ​ | 5,100 | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | —
Income tax impact on non-GAAP adjustments (1) | ​ | ​ | (4,134) | ​ | ​ | (7,260) | ​ | ​ | (4,821) | ​ | ​ | (19,355)
(Income) loss from discontinued operations | ​ | ​ | (38) | ​ | ​ | 620 | ​ | ​ | (4,638) | ​ | ​ | (245)
Adjusted net income (non-GAAP) | ​ | $ | 73,255 | ​ | $ | 59,351 | ​ | $ | 193,177 | ​ | $ | 149,000

(1) | Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

Diluted earnings per share reconciliation to adjusted earnings per share (shares in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | 2025 | ​ | 2024 | ​ | 2025 | ​ | 2024
Diluted earnings per share (GAAP) | ​ | $ | 1.59 | ​ | $ | 0.93 | ​ | $ | 4.74 | ​ | $ | 2.14
Effect on diluted earnings per share: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring expense | ​ | ​ | 0.01 | ​ | ​ | 0.01 | ​ | ​ | 0.08 | ​ | ​ | 0.03
Business integration expense | ​ | ​ | - | ​ | ​ | 0.47 | ​ | ​ | - | ​ | ​ | 0.75
Amortization of acquired intangible assets | ​ | ​ | 0.07 | ​ | ​ | 0.21 | ​ | ​ | 0.22 | ​ | ​ | 0.69
Write-off of debt discount and issuance costs, litigation reserve, asset impairments, loss on assets held for sale, and debt modification costs | ​ | ​ | 0.21 | ​ | ​ | 0.05 | ​ | ​ | 0.09 | ​ | ​ | 0.52
Strategic advisory costs | ​ | ​ | 0.13 | ​ | ​ | - | ​ | ​ | 0.13 | ​ | ​ | -
Income tax impact on non-GAAP adjustments (1) | ​ | ​ | (0.11) | ​ | ​ | (0.18) | ​ | ​ | (0.12) | ​ | ​ | (0.47)
(Income) loss from discontinued operations | ​ | ​ | (0.00) | ​ | ​ | 0.02 | ​ | ​ | (0.12) | ​ | ​ | (0.01)
Adjusted earnings per share (non-GAAP) | ​ | $ | 1.92 | ​ | $ | 1.50 | ​ | $ | 5.01 | ​ | $ | 3.65
Diluted shares used in non-GAAP EPS calculation | ​ | ​ | 38,233 | ​ | ​ | 39,636 | ​ | ​ | 38,583 | ​ | ​ | 40,874

(1) | Represents the income tax impact of non-GAAP continuing operations adjustments that is recognized in our GAAP financial statements.

42

Table of Contents

Reconciliation to adjusted EBITDA (in thousands):

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​ | Nine Months Ended
​ | ​ | March 31, | ​ | March 31,
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Increase/(Decrease) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Increase/(Decrease) | ​
​ | ​ | 2025 | ​ | 2024 | ​ | $ | ​ | % | ​ | ​ | 2025 | ​ | 2024 | ​ | $ | ​ | % | ​
Chamberlain: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income (GAAP) | ​ | $ | 47,516 | ​ | $ | 43,349 | ​ | $ | 4,167 | ​ | 9.6 | % | ​ | $ | 115,716 | ​ | $ | 97,313 | ​ | $ | 18,403 | ​ | 18.9 | %
Restructuring expense | ​ | ​ | (23) | ​ | ​ | — | ​ | ​ | (23) | ​ | ​ | ​ | ​ | ​ | 1,912 | ​ | ​ | — | ​ | ​ | 1,912 | ​ | ​ | ​
Depreciation | ​ | ​ | 5,350 | ​ | ​ | 4,938 | ​ | ​ | 412 | ​ | ​ | ​ | ​ | ​ | 16,184 | ​ | ​ | 13,840 | ​ | ​ | 2,344 | ​ | ​ | ​
Amortization of cloud computing implementation assets | ​ | ​ | 786 | ​ | ​ | 374 | ​ | ​ | 412 | ​ | ​ | ​ | ​ | ​ | 2,253 | ​ | ​ | 950 | ​ | ​ | 1,303 | ​ | ​ | ​
Stock-based compensation | ​ | ​ | 3,178 | ​ | ​ | 1,795 | ​ | ​ | 1,383 | ​ | ​ | ​ | ​ | ​ | 10,290 | ​ | ​ | 6,791 | ​ | ​ | 3,499 | ​ | ​ | ​
Adjusted EBITDA (non-GAAP) | ​ | $ | 56,807 | ​ | $ | 50,456 | ​ | $ | 6,351 | ​ | 12.6 | % | ​ | $ | 146,355 | ​ | $ | 118,894 | ​ | $ | 27,461 | ​ | 23.1 | %
Adjusted EBITDA margin (non-GAAP) | ​ | ​ | 29.5 | % | ​ | 29.6 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 27.0 | % | ​ | 25.5 | % | ​ | ​ | ​ | ​ | ​
Walden: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income (GAAP) | ​ | $ | 45,194 | ​ | $ | 23,585 | ​ | $ | 21,609 | ​ | 91.6 | % | ​ | $ | 133,929 | ​ | $ | 47,121 | ​ | $ | 86,808 | ​ | 184.2 | %
Restructuring expense | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | (776) | ​ | ​ | 776 | ​ | ​ | ​
Amortization of acquired intangible assets | ​ | ​ | 2,805 | ​ | ​ | 8,286 | ​ | ​ | (5,481) | ​ | ​ | ​ | ​ | ​ | 8,415 | ​ | ​ | 28,296 | ​ | ​ | (19,881) | ​ | ​ | ​
Litigation reserve | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (5,550) | ​ | ​ | 18,500 | ​ | ​ | (24,050) | ​ | ​ | ​
Depreciation | ​ | ​ | 1,951 | ​ | ​ | 1,835 | ​ | ​ | 116 | ​ | ​ | ​ | ​ | ​ | 5,428 | ​ | ​ | 5,735 | ​ | ​ | (307) | ​ | ​ | ​
Amortization of cloud computing implementation assets | ​ | ​ | 763 | ​ | ​ | 379 | ​ | ​ | 384 | ​ | ​ | ​ | ​ | ​ | 2,242 | ​ | ​ | 946 | ​ | ​ | 1,296 | ​ | ​ | ​
Stock-based compensation | ​ | ​ | 3,288 | ​ | ​ | 1,770 | ​ | ​ | 1,518 | ​ | ​ | ​ | ​ | ​ | 9,354 | ​ | ​ | 5,822 | ​ | ​ | 3,532 | ​ | ​ | ​
Adjusted EBITDA (non-GAAP) | ​ | $ | 54,001 | ​ | $ | 35,855 | ​ | $ | 18,146 | ​ | 50.6 | % | ​ | $ | 153,818 | ​ | $ | 105,644 | ​ | $ | 48,174 | ​ | 45.6 | %
Adjusted EBITDA margin (non-GAAP) | ​ | ​ | 30.3 | % | ​ | 23.8 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 30.1 | % | ​ | 24.1 | % | ​ | ​ | ​ | ​ | ​
Medical and Veterinary: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating income (GAAP) | ​ | $ | 17,800 | ​ | $ | 22,759 | ​ | $ | (4,959) | ​ | (21.8) | % | ​ | $ | 53,934 | ​ | $ | 59,142 | ​ | $ | (5,208) | ​ | (8.8) | %
Restructuring expense | ​ | ​ | 121 | ​ | ​ | 194 | ​ | ​ | (73) | ​ | ​ | ​ | ​ | ​ | 236 | ​ | ​ | 379 | ​ | ​ | (143) | ​ | ​ | ​
Depreciation | ​ | ​ | 2,785 | ​ | ​ | 3,033 | ​ | ​ | (248) | ​ | ​ | ​ | ​ | ​ | 8,098 | ​ | ​ | 8,897 | ​ | ​ | (799) | ​ | ​ | ​
Amortization of cloud computing implementation assets | ​ | ​ | 304 | ​ | ​ | 141 | ​ | ​ | 163 | ​ | ​ | ​ | ​ | ​ | 902 | ​ | ​ | 331 | ​ | ​ | 571 | ​ | ​ | ​
Stock-based compensation | ​ | ​ | 1,848 | ​ | ​ | 851 | ​ | ​ | 997 | ​ | ​ | ​ | ​ | ​ | 5,613 | ​ | ​ | 3,687 | ​ | ​ | 1,926 | ​ | ​ | ​
Adjusted EBITDA (non-GAAP) | ​ | $ | 22,858 | ​ | $ | 26,978 | ​ | $ | (4,120) | ​ | (15.3) | % | ​ | $ | 68,783 | ​ | $ | 72,436 | ​ | $ | (3,653) | ​ | (5.0) | %
Adjusted EBITDA margin (non-GAAP) | ​ | ​ | 24.0 | % | ​ | 29.4 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 24.7 | % | ​ | 26.9 | % | ​ | ​ | ​ | ​ | ​
Home Office: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating loss (GAAP) | ​ | $ | (20,001) | ​ | $ | (27,968) | ​ | $ | 7,967 | ​ | 28.5 | % | ​ | $ | (38,962) | ​ | $ | (55,045) | ​ | $ | 16,083 | ​ | 29.2 | %
Restructuring expense | ​ | ​ | 412 | ​ | ​ | 279 | ​ | ​ | 133 | ​ | ​ | ​ | ​ | ​ | 778 | ​ | ​ | 1,614 | ​ | ​ | (836) | ​ | ​ | ​
Business integration expense | ​ | ​ | — | ​ | ​ | 18,450 | ​ | ​ | (18,450) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | 30,621 | ​ | ​ | (30,621) | ​ | ​ | ​
Asset impairments | ​ | ​ | 6,442 | ​ | ​ | — | ​ | ​ | 6,442 | ​ | ​ | ​ | ​ | ​ | 6,442 | ​ | ​ | — | ​ | ​ | 6,442 | ​ | ​ | ​
Strategic advisory costs | ​ | ​ | 5,100 | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | ​ | ​ | ​ | 5,100 | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | ​
Loss on assets held for sale | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | 647 | ​ | ​ | (647) | ​ | ​ | ​
Debt modification costs | ​ | ​ | — | ​ | ​ | 848 | ​ | ​ | (848) | ​ | ​ | ​ | ​ | ​ | 712 | ​ | ​ | 848 | ​ | ​ | (136) | ​ | ​ | ​
Depreciation | ​ | ​ | 188 | ​ | ​ | 692 | ​ | ​ | (504) | ​ | ​ | ​ | ​ | ​ | 557 | ​ | ​ | 1,407 | ​ | ​ | (850) | ​ | ​ | ​
Stock-based compensation | ​ | ​ | 1,949 | ​ | ​ | 1,484 | ​ | ​ | 465 | ​ | ​ | ​ | ​ | ​ | 5,924 | ​ | ​ | 3,105 | ​ | ​ | 2,819 | ​ | ​ | ​
Adjusted EBITDA (non-GAAP) | ​ | $ | (5,910) | ​ | $ | (6,215) | ​ | $ | 305 | ​ | 4.9 | % | ​ | $ | (19,449) | ​ | $ | (16,803) | ​ | $ | (2,646) | ​ | (15.7) | %
Adtalem Global Education: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income (GAAP) | ​ | $ | 60,832 | ​ | $ | 36,821 | ​ | $ | 24,011 | ​ | 65.2 | % | ​ | $ | 182,853 | ​ | $ | 87,358 | ​ | $ | 95,495 | ​ | 109.3 | %
(Income) loss from discontinued operations | ​ | ​ | (38) | ​ | ​ | 620 | ​ | ​ | (658) | ​ | ​ | ​ | ​ | ​ | (4,638) | ​ | ​ | (245) | ​ | ​ | (4,393) | ​ | ​ | ​
Interest expense | ​ | ​ | 13,074 | ​ | ​ | 16,560 | ​ | ​ | (3,486) | ​ | ​ | ​ | ​ | ​ | 41,465 | ​ | ​ | 48,910 | ​ | ​ | (7,445) | ​ | ​ | ​
Other income, net | ​ | ​ | (1,898) | ​ | ​ | (2,871) | ​ | ​ | 973 | ​ | ​ | ​ | ​ | ​ | (6,779) | ​ | ​ | (8,648) | ​ | ​ | 1,869 | ​ | ​ | ​
Provision for income taxes | ​ | ​ | 18,539 | ​ | ​ | 10,595 | ​ | ​ | 7,944 | ​ | ​ | ​ | ​ | ​ | 51,716 | ​ | ​ | 21,156 | ​ | ​ | 30,560 | ​ | ​ | ​
Operating income (GAAP) | ​ | ​ | 90,509 | ​ | ​ | 61,725 | ​ | ​ | 28,784 | ​ | ​ | ​ | ​ | ​ | 264,617 | ​ | ​ | 148,531 | ​ | ​ | 116,086 | ​ | ​ | ​
Depreciation and amortization | ​ | ​ | 14,932 | ​ | ​ | 19,678 | ​ | ​ | (4,746) | ​ | ​ | ​ | ​ | ​ | 44,079 | ​ | ​ | 60,402 | ​ | ​ | (16,323) | ​ | ​ | ​
Stock-based compensation | ​ | ​ | 10,263 | ​ | ​ | 5,900 | ​ | ​ | 4,363 | ​ | ​ | ​ | ​ | ​ | 31,181 | ​ | ​ | 19,405 | ​ | ​ | 11,776 | ​ | ​ | ​
Restructuring expense | ​ | ​ | 510 | ​ | ​ | 473 | ​ | ​ | 37 | ​ | ​ | ​ | ​ | ​ | 2,926 | ​ | ​ | 1,217 | ​ | ​ | 1,709 | ​ | ​ | ​
Business integration expense | ​ | ​ | — | ​ | ​ | 18,450 | ​ | ​ | (18,450) | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | 30,621 | ​ | ​ | (30,621) | ​ | ​ | ​
Litigation reserve | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | (5,550) | ​ | ​ | 18,500 | ​ | ​ | (24,050) | ​ | ​ | ​
Asset impairments | ​ | ​ | 6,442 | ​ | ​ | — | ​ | ​ | 6,442 | ​ | ​ | ​ | ​ | ​ | 6,442 | ​ | ​ | — | ​ | ​ | 6,442 | ​ | ​ | ​
Strategic advisory costs | ​ | ​ | 5,100 | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | ​ | ​ | ​ | 5,100 | ​ | ​ | — | ​ | ​ | 5,100 | ​ | ​ | ​
Loss on assets held for sale | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | ​ | ​ | ​ | — | ​ | ​ | 647 | ​ | ​ | (647) | ​ | ​ | ​
Debt modification costs | ​ | ​ | — | ​ | ​ | 848 | ​ | ​ | (848) | ​ | ​ | ​ | ​ | ​ | 712 | ​ | ​ | 848 | ​ | ​ | (136) | ​ | ​ | ​
Adjusted EBITDA (non-GAAP) | ​ | $ | 127,756 | ​ | $ | 107,074 | ​ | $ | 20,682 | ​ | 19.3 | % | ​ | $ | 349,507 | ​ | $ | 280,171 | ​ | $ | 69,336 | ​ | 24.7 | %
Adjusted EBITDA margin (non-GAAP) | ​ | ​ | 27.4 | % | ​ | 25.9 | % | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 26.3 | % | ​ | 23.8 | % | ​ | ​ | ​ | ​ | ​

​

​

​

43

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in Adtalem’s market risk exposure during the first nine months of fiscal year 2025 from those set forth in Item 7A. “Quantitative and Qualitative Disclosures About Market Risk” contained in our 2024 Form 10-K.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Based on an evaluation of our disclosure controls and procedures (as such term is defined in Exchange Act Rule 13a-15(e)) that was conducted under the supervision and with the participation of Adtalem’s management, including our Chief Executive Officer and Chief Financial Officer, our Chief Executive Officer and Chief Financial Officer concluded that Adtalem’s disclosure controls and procedures were effective as of March 31, 2025.

Changes in Internal Control over Financial Reporting

There were no changes during the third quarter of fiscal year 2025 in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings

For information regarding legal proceedings, see Note 17 “Commitments and Contingencies” to the Consolidated Financial Statements included in Item 1. “Financial Statements.”

Item 1A. Risk Factors

There have been no material changes to Adtalem’s risk factors from those set forth since Item 1A. “Risk Factors” contained in our 2024 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Period | ​ | Total Number of Shares Purchased | ​ | Average Price Paid per Share | ​ | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) | ​ | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (1)
January 1, 2025 - January 31, 2025 | ​ | 29,894 | ​ | $ | 94.36 | ​ | 29,894 | ​ | $ | 137,313,996
February 1, 2025 - February 28, 2025 | ​ | 47,496 | ​ | $ | 101.95 | ​ | 47,496 | ​ | $ | 132,471,986
March 1, 2025 - March 31, 2025 | ​ | 714,030 | ​ | $ | 97.95 | ​ | 714,030 | ​ | $ | 62,531,497
Total | ​ | 791,420 | ​ | $ | 98.06 | ​ | 791,420 | ​ | ​ | ​

(1) | See Note 14 “Share Repurchases” to the Consolidated Financial Statements for additional information on our share repurchase programs.

44

Table of Contents

Other Purchases of Equity Securities

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Period | ​ | Total Number of Shares Purchased (1) | ​ | Average Price Paid per Share | ​ | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | ​ | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
January 1, 2025 - January 31, 2025 | ​ | 652 | ​ | $ | 94.41 | ​ | NA | ​ | NA
February 1, 2025 - February 28, 2025 | ​ | 1,514 | ​ | $ | 105.96 | ​ | NA | ​ | NA
March 1, 2025 - March 31, 2025 | ​ | 377 | ​ | $ | 98.81 | ​ | NA | ​ | NA
Total | ​ | 2,543 | ​ | $ | 101.94 | ​ | NA | ​ | NA

(1) | Represents shares delivered to Adtalem for payment of withholding taxes from employees for vesting restricted stock units and shares swapped for payment on exercise of incentive stock options pursuant to the terms of Adtalem’s stock incentive plans.

Item 5. Other Information

During the three months ended March 31, 2025, none of our directors or executive officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement” (as defined in Item 408 under Regulation S-K of the Exchange Act).

Item 6. Exhibits

​ | ​ | ​
31.1* | ​ | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
31.2* | ​ | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended
32.1* | ​ | Certifications pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS | ​ | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH | ​ | Inline XBRL Taxonomy Extension Schema Document
101.CAL | ​ | Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF | ​ | Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB | ​ | Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE | ​ | Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 | ​ | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed or furnished herewith.

​

45

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| ​ | ​
​ | Adtalem Global Education Inc.
| ​ | ​
Date: May 8, 2025 | By: | /s/ Robert J. Phelan
​ | ​ | Robert J. Phelan
​ | ​ | Senior Vice President and Chief Financial Officer
​ | ​ | (Principal Financial Officer)

​

​

​

46